<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Geriatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Geriatr</journal-id><journal-title-group><journal-title>BMC Geriatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2318</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26585952</article-id><article-id pub-id-type="pmc">4653865</article-id><article-id pub-id-type="publisher-id">148</article-id><article-id pub-id-type="doi">10.1186/s12877-015-0148-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Vitamin D supplementation to prevent depression and poor physical function in older adults: Study protocol of the D-Vitaal study, a randomized placebo-controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Koning</surname><given-names>Elisa J.</given-names></name><address><email>ej.dekoning@vumc.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>van Schoor</surname><given-names>Natasja M.</given-names></name><address><email>nm.vanschoor@vumc.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Penninx</surname><given-names>Brenda W.J.H.</given-names></name><address><email>b.penninx@vumc.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Elders</surname><given-names>Petra J.M.</given-names></name><address><email>p.elders@vumc.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Heijboer</surname><given-names>Annemieke C.</given-names></name><address><email>a.heijboer@vumc.nl</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Smit</surname><given-names>Jan. H.</given-names></name><address><email>jh.smit@ggzingeest.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Bet</surname><given-names>Pierre M.</given-names></name><address><email>pm.bet@vumc.nl</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>van Tulder</surname><given-names>Maurits W.</given-names></name><address><email>maurits.van.tulder@vu.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>den Heijer</surname><given-names>Martin</given-names></name><address><email>m.denheijer@vumc.nl</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>van Marwijk</surname><given-names>Harm W.J.</given-names></name><address><email>harm.vanmarwijk@manchester.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Lips</surname><given-names>Paul</given-names></name><address><email>p.lips@vumc.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff8"/></contrib><aff id="Aff1"><label/>EMGO Institute for Health and Care Research, VU University Medical Center, P.O. Box 7057, 1007&#x000a0;MB Amsterdam, The Netherlands </aff><aff id="Aff2"><label/>Department of Epidemiology and Biostatistics, VU University Medical Center, P.O. Box 7057, 1007&#x000a0;MB Amsterdam, The Netherlands </aff><aff id="Aff3"><label/>Department of Psychiatry, VU University Medical Center/GGZ inGeest, A.J. Ernststraat 1187, P.O. Box 1081 HL, Amsterdam, The Netherlands </aff><aff id="Aff4"><label/>Department of General Practice and Elderly Care Medicine, VU University Medical Center, P.O. Box 7057, 1007&#x000a0;MB Amsterdam, The Netherlands </aff><aff id="Aff5"><label/>Department of Clinical Chemistry, Endocrine Laboratory, VU University Medical Center, P.O. Box 7057, 1007&#x000a0;MB Amsterdam, The Netherlands </aff><aff id="Aff6"><label/>Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, P.O. Box 7057, 1007&#x000a0;MB Amsterdam, The Netherlands </aff><aff id="Aff7"><label/>Department of Health Sciences, VU University, P.O. Box 7057, 1007&#x000a0;MB Amsterdam, The Netherlands </aff><aff id="Aff8"><label/>Department of Internal Medicine, Endocrine section, VU University Medical Center, P.O. Box 7057, 1007&#x000a0;MB Amsterdam, The Netherlands </aff><aff id="Aff9"><label/>Primary Care Research Centre, Institute of Population Health, University of Manchester, Oxford Road, Manchester, M13 9PL United Kingdom </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>151</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; de Koning et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Depressive symptoms and decreased physical functioning are interrelated conditions and common in older persons, causing significant individual and societal burden. Evidence suggests that vitamin D supplementation may be beneficial for both mental and physical functioning. However, previous randomized controlled trials have yielded inconsistent results and often had suboptimal designs. This study examines the effect of vitamin D supplementation on both depressive symptoms and physical functioning in a high-risk population of older persons with low vitamin D status.</p></sec><sec><title>Methods/design</title><p>The D-Vitaal study is a randomized, double-blind, placebo-controlled trial investigating the effects of a daily dose of 1200&#x000a0;IU vitamin D<sub>3</sub> versus placebo for one year on depressive symptoms and physical functioning (primary outcomes) in older adults. Participants (<italic>N</italic>&#x02009;=&#x02009;155, age 60&#x02013;80 years) were recruited from the general population. Eligibility criteria included the presence of depressive symptoms, &#x02265;1 functional limitation and serum 25-hydroxyvitamin D levels between 15 and 50/70&#x000a0;nmol/L (depending on season). Secondary outcomes include incidence of major depressive disorder, anxiety symptoms, health-related quality of life, cognitive function and cost-effectiveness of the intervention.</p></sec><sec><title>Discussion</title><p>With this study, we aim to elucidate the effects of vitamin D supplementation on depressive symptoms and physical functioning in older persons who are at high risk of developing more substantial mental and physical problems. If effective, vitamin D supplementation can be a preventive intervention strategy that is easy to implement in the primary care setting.</p></sec><sec><title>Trial registration</title><p>Netherlands Trial Register <ext-link ext-link-type="uri" xlink:href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3845">NTR3845</ext-link>. Registered 6 February 2013.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Vitamin D</kwd><kwd>Depressive symptoms</kwd><kwd>Physical functioning</kwd><kwd>Functional limitations</kwd><kwd>Physical performance</kwd><kwd>Older adults</kwd><kwd>Randomized clinical trial</kwd><kwd>Prevention</kwd><kwd>Supplementation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Depressive symptoms are common in older adults, occurring in 8-16&#x000a0;% of persons over 55&#x000a0;years of age [<xref ref-type="bibr" rid="CR1">1</xref>]. These symptoms are associated with various adverse health outcomes, such as a higher risk of cardiovascular diseases [<xref ref-type="bibr" rid="CR2">2</xref>], hospitalization and mortality [<xref ref-type="bibr" rid="CR3">3</xref>] and reduced quality of life [<xref ref-type="bibr" rid="CR1">1</xref>]. Treatment of depression in older persons is often suboptimal, for example due to societal stigma, side-effects of anti-depressant medication, or interactions of antidepressants with other medications [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Hence, development of a simple and safe prevention strategy is pivotal.</p><p>Ageing is also commonly accompanied by a decline of physical functioning. Studies show that functional limitations and poor physical performance are highly interrelated with depressive symptoms, both cross-sectionally and longitudinally [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>], which can easily result in a downward spiral.</p><p>Previous research suggests that vitamin D supplementation may improve both mental and physical health, although evidence is inconsistent [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Vitamin D inadequacy - defined as serum 25-hydroxyvitamin D (25(OH)D) levels of &#x0003c;50&#x000a0;nmol/L [<xref ref-type="bibr" rid="CR13">13</xref>] - occurs in about 50&#x000a0;% of elderly persons from Western countries [<xref ref-type="bibr" rid="CR14">14</xref>]. Vitamin D is synthesized in the skin under the influence of sunlight. In addition, some vitamin D is retrieved from food, especially from fatty fish [<xref ref-type="bibr" rid="CR15">15</xref>]. Causes of vitamin D deficiency in older persons include declining efficiency of the skin to synthesize vitamin D, a lower amount of sun exposure and reduced nutritional intake [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Several biological mechanisms that can explain the relationship of vitamin D deficiency with depressive symptoms and poor physical functioning have been suggested (see also Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The active metabolite of vitamin D - 1,25 dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) - is synthesized in the brain by the enzyme 1&#x003b1;-hydroxylase [<xref ref-type="bibr" rid="CR17">17</xref>], enabling local activation of vitamin D. Moreover, the vitamin D receptor (VDR) is present in several brain areas important for depression and emotional behaviour, including the hippocampus and hypothalamus [<xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, 1,25(OH)<sub>2</sub>D promotes the synthesis of depression-related monoamine neurotransmitters such as serotonin [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] and has a general protective effect on brain functioning through immunomodulation, anti-inflammatory action and promotion of neuroplasticity [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Regarding physical functioning, the VDR has been observed in the cerebellum [<xref ref-type="bibr" rid="CR18">18</xref>], which is an important brain area for mobility, gait and balance [<xref ref-type="bibr" rid="CR22">22</xref>]. In addition, the presence of 1,25(OH)<sub>2</sub>D and the VDR in muscle tissue facilitates muscle contraction speed, muscle power and cell growth [<xref ref-type="bibr" rid="CR19">19</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Pathophysiological effects of low vitamin D status on mental and physical functioning</p></caption><graphic xlink:href="12877_2015_148_Fig1_HTML" id="MO1"/></fig></p><p>Prospective cohort studies suggest that vitamin D deficiency is associated with depressive symptoms, poor physical performance and functional limitations [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. In the InChianti study, vitamin D deficiency at baseline almost doubled the risk of depressive symptoms after three and six years and was also associated with lower physical performance [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Evidence from randomized controlled trials (RCTs) is diffuse and inconclusive. Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> provide an overview of previous RCTs examining the effects of vitamin D supplementation on depressive symptoms and physical functioning. Only RCTs that included adults and had a sample size of &#x02265;40 were selected (search strategy available from the author). From these tables, it can be concluded that previous RCTs have been heterogeneous with respect to sample size, age range of the participants, dosage of the supplementation, duration of the intervention and outcome measures. Moreover, only a very limited amount of studies included high-risk participants, i.e. persons with low serum 25(OH)D and mental/physical symptoms at baseline. It can be expected that supplementation is more effective and relevant in persons with low baseline 25(OH)D levels and in persons with clinically relevant depressive symptoms or reduced physical functioning.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Overview of RCTs that examined the effect of vitamin D supplementation on depression</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Trial, year</th><th>Participants</th><th>Low vitD as inclusion criterion?</th><th>Depressive symptoms as inclusion criterion?</th><th>Intervention</th><th>Outcome</th><th>Results</th></tr></thead><tbody><tr><td>Lansdowne et al., 1998 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td>44 healthy adults, age 18&#x02013;43&#x000a0;yrs., 77&#x000a0;% female.</td><td>No</td><td>No</td><td>400 or 800&#x000a0;IU/day vitD<sub>3</sub> vs. placebo for 5&#x000a0;days in late winter.</td><td>Positive and negative affect (PANAS).</td><td>Improved positive affect, possibly reduced negative affect in both vitD groups.</td></tr><tr><td>Jorde et al., 2008 [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td>441 overweight/obese outpatients or community dwellers, age 21&#x02013;70&#x000a0;yrs., 64&#x000a0;% female.</td><td>No</td><td>No</td><td>20,000 or 40,000&#x000a0;IU/week vitD<sub>3</sub> vs. placebo for 1&#x000a0;yr.</td><td>Depressive symptoms (BDI).</td><td>Lower depression scores in both vitD groups. Effect more pronounced in persons with higher baseline depression scores.</td></tr><tr><td>Sanders et al., 2011 [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td>2012 community dwelling women, age 70+ yrs.</td><td>No</td><td>No</td><td>500,000&#x000a0;IU vitD<sub>3</sub> vs. placebo once every autumn/winter for 3&#x02013;5&#x000a0;yrs.</td><td>Mental well-being (GHQ, SF-12, WHO Well-Being index.</td><td>NS.</td></tr><tr><td>Dean et al., 2011 [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td>128 healthy adults, age 18&#x02013;30&#x000a0;yrs., 57&#x000a0;% female.</td><td>No</td><td>No</td><td>5000&#x000a0;IU/day vitD<sub>3</sub> vs. placebo for 6&#x000a0;weeks.</td><td>Depressive symptoms (BDI).</td><td>NS.</td></tr><tr><td>Bertone-Johnson et al., 2012 [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td>2263 post-menopausal women, age 50&#x02013;79&#x000a0;yrs.</td><td>No</td><td>No</td><td>400&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;1000&#x000a0;mg/day calcium vs. placebo for 2&#x000a0;yrs.</td><td>Depressive symptoms, MDD (Burnam scale, antidepressant use).</td><td>NS.</td></tr><tr><td>Yalamanchiliet al., 2012 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td>412 post-menopausal women, age 65&#x02013;77&#x000a0;yrs.</td><td>No</td><td>No</td><td>Calcitriol 0.25&#x000a0;g twice daily vs. placebo&#x02009;+&#x02009;estrogens vs. placebo for 3&#x000a0;yrs.</td><td>Depressive symptoms (GDS).</td><td>NS.</td></tr><tr><td>Khoraminya et al., 2012 [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td>40 outpatients with MDD, age 18&#x02013;65&#x000a0;yrs., 85&#x000a0;% female.</td><td>No</td><td>Yes: MDD diagnosis.</td><td>1500&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;20&#x000a0;mg fluoxetine vs. fluoxetine alone for 8&#x000a0;weeks.</td><td>Depression severity (HDRS), depressive symptoms (BDI).</td><td>Vitamin D&#x02009;+&#x02009;fluoxetine superior to fluoxetine alone in reducing depressive symptoms.</td></tr><tr><td>Kj&#x000e6;rgaard et al., 2012 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td>230 community dwellers, age 30&#x02013;75&#x000a0;yrs., 56&#x000a0;% female.</td><td>Yes: 25(OH)D &#x0003c;55&#x000a0;nmol/L.</td><td>No</td><td>40,000&#x000a0;IU/week vitD<sub>3</sub> vs placebo for 6&#x000a0;months.</td><td>Depressive symptoms (BDI, HADS, MADRS).</td><td>NS.</td></tr><tr><td colspan="7">Studies published after commencement of the D-Vitaal trial:</td></tr><tr><td>Mozaffari- Khosravi et al., 2013 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td>109 psychiatric outpatients, age 20&#x02013;60&#x000a0;yrs., 72&#x000a0;% female.</td><td>Yes: 25(OH)D&#x02009;&#x0003c;&#x02009;40&#x000a0;nmol/L.</td><td>Yes: BDI score &#x02265;17.</td><td>Single dose of 150,000 or 300,000&#x000a0;IU vitD<sub>3</sub> vs. no injection.</td><td>Depressive symptoms after 3&#x000a0;months (BDI).</td><td>Reduced depressive symptoms in 300,000&#x000a0;IU group.</td></tr></tbody></table><table-wrap-foot><p>Systematic review of RCTs (inception - July 2015). Search strategy available from author. NS: not significant</p><p>PANAS: Positive And Negative Affect Schedule; BDI: Beck Depression Inventory; GHQ: General Health Questionnaire; SF-12: Short Form health survey &#x02013; 12 item version; MDD: major depressive disorder; GDS: Geriatric Depression Scale; HDRS: Hamilton Depression Rating Scale; HADS: Hospital Anxiety and Depression Scale; MADRS: Montgomery-&#x000c5;sberg Depression Rating Scale</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Overview of RCTs that examined the effect of vitamin D supplementation on physical functioning</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Trial, year</th><th>Participants</th><th>Low vitD as inclusion criterion?</th><th>Poor physical function as inclusion criterion?</th><th>Intervention</th><th>Outcome</th><th>Results</th></tr></thead><tbody><tr><td>Grady et al., 1991 [<xref ref-type="bibr" rid="CR74">74</xref>]<sup>a</sup>
</td><td>98 community dwellers, age 70+ yrs., 54&#x000a0;% female.</td><td>No</td><td>No</td><td>0.25&#x000a0;&#x003bc;g 1,25(OH)<sub>2</sub>D<sub>3</sub> twice daily vs. placebo for 6&#x000a0;months.</td><td>Muscle strength (quadriceps).</td><td>NS.</td></tr><tr><td>Pfeifer et al., 2000 [<xref ref-type="bibr" rid="CR75">75</xref>]</td><td>148 community dwelling females, age 70+ yrs.</td><td>Yes: 25(OH)D &#x0003c;50&#x000a0;nmol/L.</td><td>No</td><td>800&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;1200&#x000a0;mg/day calcium vs. calcium alone for 8&#x000a0;weeks.</td><td>Body sway.</td><td>Reduced sway in vitD group.</td></tr><tr><td>Bischoff et al., 2003 [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td>122 geriatric inpatient females, age 63&#x02013;99&#x000a0;yrs.</td><td>No</td><td>No</td><td>800&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;1200&#x000a0;mg/day calcium vs. calcium alone for 12&#x000a0;weeks.</td><td>Musculoskeletal function (knee muscle strength, grip strength, TUG).</td><td>Improved musculoskeletal function in vitD group.</td></tr><tr><td>Kenny et al., 2003 [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td>60 community dwelling males, age 65&#x02013;87&#x000a0;yrs.</td><td>No</td><td>No</td><td>1000&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;500&#x000a0;mg/day calcium vs. calcium alone for 6&#x000a0;months.</td><td>Muscle strength and power (leg, handgrip), physical performance (SPPB, TUG, supine-to-stand test).</td><td>NS.</td></tr><tr><td>Latham et al., 2003 [<xref ref-type="bibr" rid="CR78">78</xref>]</td><td>243 geriatric in- and outpatients, age 65+ yrs., 53&#x000a0;% female.</td><td>No</td><td>Yes: frailty.</td><td>Single dose of 300,000&#x000a0;IU vitD<sub>2</sub>vs. placebo&#x02009;+&#x02009;exercise training vs. social visits for 10&#x000a0;weeks.</td><td>Physical performance (knee strength, balance, TUG, gait speed) after 3 and 6&#x000a0;months.</td><td>NS.</td></tr><tr><td>Dhesi et al., 2004 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td>139 outpatients, age 65+ yrs., 78&#x000a0;% female.</td><td>Yes: 25(OH)D &#x0003c;30&#x000a0;nmol/L.</td><td>Yes: history of falls.</td><td>Single intramuscular injection of 600,000&#x000a0;IU vitD<sub>2</sub> vs. placebo.</td><td>Postural sway, physical performance (gait speed, chair stands, stair climbing), quadriceps strength after 6&#x000a0;months.</td><td>Improved physical performance and sway in vitD group.</td></tr><tr><td>Gallagher, 2004 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td>289 postmenopausal females, mean age 72&#x000a0;yrs.</td><td>No</td><td>No</td><td>0.5&#x000a0;&#x003bc;g/day calcitriol vs. placebo&#x02009;+&#x02009;estrogen / progesterone treatment vs. placebo for 3&#x000a0;yrs.</td><td>Physical performance (grip strength, gait speed, chair stands).</td><td>Improved chair stands and gait speed in vitD group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.1).</td></tr><tr><td>Sato et al., 2005 [<xref ref-type="bibr" rid="CR80">80</xref>]</td><td>96 females with post-stroke hemiplegia, mean age 74&#x000a0;yrs.</td><td>No</td><td>No</td><td>1000&#x000a0;IU/day vitD<sub>2</sub> vs. placebo for 2&#x000a0;yrs.</td><td>Muscle strength (of the intact hip).</td><td>Improved muscle strength in vitD group.</td></tr><tr><td>Bischoff-Ferrari et al., 2006 [<xref ref-type="bibr" rid="CR81">81</xref>]</td><td>64 institutionalized older females, age 65&#x02013;97&#x000a0;yrs.</td><td>No</td><td>No</td><td>800&#x000a0;IU vitD<sub>3</sub>&#x02009;+&#x02009;1200&#x000a0;mg/day calcium vs. calcium alone for 3&#x000a0;months.</td><td>Postural and dynamic balance.</td><td>NS.</td></tr><tr><td>Bunout et al., 2006 [<xref ref-type="bibr" rid="CR82">82</xref>]</td><td>92 community dwellers, age 70+ yrs., 88&#x000a0;% female.</td><td>Yes: 25(OH)D &#x0003c;40&#x000a0;nmol/L.</td><td>No</td><td>400&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;800&#x000a0;mg/day calcium vs. calcium alone&#x02009;+&#x02009;exercise training vs. control for 9&#x000a0;months.</td><td>Muscle strength (quadriceps, hand grip), gait speed, physical performance (SPPB, TUG), postural sway.</td><td>Improved gait speed and sway in vitD group.</td></tr><tr><td>Smedshaug et al., 2007 [<xref ref-type="bibr" rid="CR83">83</xref>]</td><td>60 institutionalized persons, mean age 82&#x000a0;yrs., 65&#x000a0;% female.</td><td>No</td><td>No</td><td>400&#x000a0;IU/day vitD<sub>3</sub> vs. placebo for 1&#x000a0;yr.</td><td>Grip strength.</td><td>NS.</td></tr><tr><td>Brunner et al., 2008 [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td>2364 postmenopausal females, age 50&#x02013;79&#x000a0;yrs.</td><td>No</td><td>No</td><td>400&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;1000&#x000a0;mg/day calcium vs. placebo for 5&#x000a0;yrs.</td><td>Grip strength, chair stands, gait speed.</td><td>NS.</td></tr><tr><td>Moreira-Pfrimer et al., 2009 [<xref ref-type="bibr" rid="CR85">85</xref>]</td><td>46 institutionalized geriatric patients, age 62&#x02013;94&#x000a0;yrs., 79&#x000a0;% female.</td><td>No</td><td>No</td><td>150,000&#x000a0;IU/month vitD<sub>3</sub> for 2&#x000a0;months, followed by 90,000&#x000a0;IU/month vs. placebo for 4&#x000a0;months + . 1000&#x000a0;mg/day calcium.</td><td>Lower limb muscle strength (hip, knee).</td><td>Improved lower limb muscle strength (both hip and knee) in vitD group.</td></tr><tr><td>Pfeifer et al., 2009 [<xref ref-type="bibr" rid="CR86">86</xref>]</td><td>242 community dwellers, age 70&#x02013;94&#x000a0;yrs., 75&#x000a0;% female.</td><td>Yes: 25(OH)D &#x0003c;78&#x000a0;nmol/L.</td><td>No</td><td>800&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;1000&#x000a0;mg/day calcium vs calcium alone for 12&#x000a0;months.</td><td>Muscle strength (quadriceps), body sway, TUG.</td><td>Improved quadriceps strength, sway and TUG performance in vitD group.</td></tr><tr><td>Songpatanasilp et al., 2009 [<xref ref-type="bibr" rid="CR87">87</xref>]<sup>a</sup>
</td><td>42 postmenopausal females, age 65+ yrs.</td><td>Yes: hypovitaminosis D (range NR)</td><td>No</td><td>0.5&#x000a0;mg/day alfacalcidol&#x02009;+&#x02009;1500&#x000a0;mg/day calcium vs. calcium alone for 12&#x000a0;weeks.</td><td>Muscle strength (quadriceps).</td><td>Improved quadriceps muscle strength in vitD group.</td></tr><tr><td>Janssen et al., 2010 [<xref ref-type="bibr" rid="CR88">88</xref>]<sup>a</sup>
</td><td>70 female geriatric outpatients, age 65+ yrs.</td><td>Yes: 25(OH)D 20&#x02013;50&#x000a0;nmol/L.</td><td>No</td><td>400&#x000a0;IU/day vitD<sub>3</sub>&#x02009;+&#x02009;500&#x000a0;mg/day calcium vs. calcium alone for 6&#x000a0;months.</td><td>Muscle strength (knee, leg, hand grip), mobility (TUG), gait speed.</td><td>NS.</td></tr><tr><td>Lips et al., 2010 [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>226 community dwellers, age 70+ yrs., % female NR.</td><td>Yes: 25(OH)D 15&#x02013;50&#x000a0;nmol/L.</td><td>No</td><td>8400&#x000a0;IU/week vitD<sub>3</sub> vs. placebo for 16&#x000a0;weeks.</td><td>Postural sway, SPPB.</td><td>Reduced sway in vitD group, only in persons with higher baseline sway.</td></tr><tr><td>Witham et al., 2010 [<xref ref-type="bibr" rid="CR90">90</xref>]</td><td>105 patients with systolic heart failure, age 70+ yrs., 34&#x000a0;% female.</td><td>Yes: 25(OH)D &#x0003c;50&#x000a0;nmol/L.</td><td>No</td><td>100,000&#x000a0;IU vitD<sub>2</sub> vs. placebo at baseline and after 10&#x000a0;weeks.</td><td>Gait speed, mobility (TUG), functional limitations.</td><td>NS.</td></tr><tr><td>Zhu et al., 2010 [<xref ref-type="bibr" rid="CR91">91</xref>]</td><td>261 community dwelling females, age 70&#x02013;90&#x000a0;yrs.</td><td>Yes: 25(OH)D &#x0003c;60&#x000a0;nmol/L.</td><td>No</td><td>VitD<sub>2</sub> 1000&#x000a0;IU/day&#x02009;+&#x02009;1000&#x000a0;mg/day calcium vs. calcium alone for 1&#x000a0;yr.</td><td>Lower limb muscle strength (ankle, knee, hip), mobility (TUG).</td><td>Improved hip muscle strength and mobility in vitD group, only in persons with lowest baseline function scores.</td></tr><tr><td>Glendenning et al., 2012 [<xref ref-type="bibr" rid="CR92">92</xref>]</td><td>686 postmenopausal females, age 70+ yrs.</td><td>No</td><td>No</td><td>150,000&#x000a0;IU vitD<sub>3</sub> vs. placebo at baseline and after 3 and 6&#x000a0;months.</td><td>Grip strength, mobility (TUG).</td><td>NS.</td></tr><tr><td>Hornikx et al., 2012 [<xref ref-type="bibr" rid="CR93">93</xref>]</td><td>49 COPD patients, age 50+ yrs., 24&#x000a0;% female.</td><td>No</td><td>No</td><td>100,000&#x000a0;IU vitD<sub>3</sub>/month vs. placebo for 3&#x000a0;months.</td><td>Muscle strength (inspiratory, quadriceps), gait speed, maximal exercise capacity (cycle ergometer test)</td><td>Improved inspiratory muscle strength in vitD group.</td></tr><tr><td>Kampman et al., 2012 [<xref ref-type="bibr" rid="CR94">94</xref>]</td><td>68 multiple sclerosis patients, age 21&#x02013;50&#x000a0;yrs., 71&#x000a0;% female.</td><td>No</td><td>No</td><td>20,000&#x000a0;IU vitD<sub>3</sub>/week vs. placebo for 2&#x000a0;yrs.</td><td>Grip strength.</td><td>NS.</td></tr><tr><td colspan="7">Studies published after commencement of the D-Vitaal trial:</td></tr><tr><td>Hara et al., 2013 [<xref ref-type="bibr" rid="CR95">95</xref>]</td><td>94 postmenopausal females with osteoporosis, age 55&#x02013;75&#x000a0;yrs.</td><td>No</td><td>No</td><td>1&#x000a0;&#x003bc;g/day alfacalcidol&#x02009;+&#x02009;200&#x000a0;mg/day calcium&#x02009;+&#x02009;35&#x000a0;mg/week alendronate vs. calcium and alendronate alone for 4&#x000a0;months.</td><td>Muscle strength (back extensor).</td><td>Improved back extensor strength in younger vitD subgroup.</td></tr><tr><td>McAlindon et al., 2013 [<xref ref-type="bibr" rid="CR96">96</xref>]</td><td>146 adults with knee osteoarthritis (OA), age 45+ yrs., 61&#x000a0;% female.</td><td>No</td><td>Yes: presence of symptomatic knee osteoarthritis.</td><td>2000&#x000a0;IU/day vitD<sub>3</sub> with dose escalation to obtain serum levels of &#x0003e;90&#x000a0;nmol/L vs. placebo for 2&#x000a0;yrs.</td><td>Gait speed, chair stands.</td><td>NS.</td></tr><tr><td>Sanghi et al., 2013 [<xref ref-type="bibr" rid="CR97">97</xref>]</td><td>103 adults with knee osteoarthritis, age 40&#x02013;74&#x000a0;yrs., 64&#x000a0;% female.</td><td>No</td><td>Yes: presence of symptomatic knee osteoarthritis.</td><td>60,000&#x000a0;IU/day vitD<sub>3</sub> for 10&#x000a0;days followed by 60,000&#x000a0;IU/month vs. placebo for 12&#x000a0;months.</td><td>Functional limitations (WOMAC).</td><td>Small improvement of physical function in vitD group.</td></tr><tr><td>Knutsen et al., 2014 [<xref ref-type="bibr" rid="CR98">98</xref>]</td><td>215 non-western immigrants, age 18&#x02013;50&#x000a0;yrs., 73&#x000a0;% female.</td><td>No</td><td>No</td><td>1000 or 400&#x000a0;IU vitD3/day vs. placebo for 16&#x000a0;weeks.</td><td>Grip strength, chair stands, muscle strength and power.</td><td>NS.</td></tr><tr><td>Wood et al., 2014 [<xref ref-type="bibr" rid="CR99">99</xref>]</td><td>293 postmenopausal females, age 60&#x02013;70&#x000a0;yrs.</td><td>No</td><td>No</td><td>400 or 1000&#x000a0;IU/day vitD<sub>3</sub> vs. placebo for 12&#x000a0;months.</td><td>Grip strength.</td><td>NS.</td></tr><tr><td>Rolighed et al., 2015 [<xref ref-type="bibr" rid="CR100">100</xref>]</td><td>46 patients with primary hyperparathyroidism, age 29&#x02013;77&#x000a0;yrs., 76&#x000a0;% female.</td><td>Yes, 25(OH)D &#x0003c;80&#x000a0;nmol/L.</td><td>No</td><td>2800&#x000a0;IU/day vitD<sub>3</sub> vs. placebo for 12&#x000a0;months.</td><td>Muscle strength (knee, elbow, hand grip), chair stands, mobility (TUG), postural sway.</td><td>NS.</td></tr></tbody></table><table-wrap-foot><p>Systematic review of RCTs (inception - July 2015). Search strategy available from author. NS: not significant. NR: not reported.</p><p>TUG: Timed Up-and-Go test; SPPB: Short Physical Performance Battery; WOMAC: Western Ontario and McMaster Universities Arthritis Index.</p><p>
<sup>a</sup>only abstract available</p></table-wrap-foot></table-wrap></p><p>Four out of nine RCTs on depression (44&#x000a0;%) observed a significant positive effect of vitamin D supplementation on depressive symptoms (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). However, only two studies included persons with either low 25(OH)D or depression at baseline [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], and only one study included persons with both characteristics [<xref ref-type="bibr" rid="CR30">30</xref>]. The latter study and the study that included persons with a diagnosis of major depressive disorder (MDD) [<xref ref-type="bibr" rid="CR28">28</xref>] observed significant improvements after the supplementation.</p><p>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows that in 14 out of 28 RCTs (50&#x000a0;%), vitamin D supplementation improved physical functioning. Twelve studies included participants with either low 25(OH)D or poor physical function at baseline, and physical function improved in seven (58&#x000a0;%) of these studies. Only one study included persons with both low 25(OH)D and poor physical function [<xref ref-type="bibr" rid="CR31">31</xref>] and this trial observed a significant improvement of physical performance.</p><p>In conclusion, the effect of vitamin D supplementation seems more pronounced in persons with low 25(OH)D levels, depressive symptoms and poor physical function at baseline. However, RCTs that specifically included participants with these characteristics are scarce. Furthermore, to the best of our knowledge, no studies have examined the effect of vitamin D supplementation on the combination of mental and physical functioning, despite the fact that these are interrelated concepts.</p><p>The current RCT aims to fill this knowledge gap by investigating whether older adults at high risk for poor mental and physical health can benefit from supplementation with vitamin D. Primarily, the D-Vitaal trial examines whether vitamin D supplementation improves depressive symptoms, functional limitations and physical performance in persons with low 25(OH)D levels, clinically relevant depressive symptoms and functional limitations. Other, secondary health outcomes are assessed as well, such as incident MDD [<xref ref-type="bibr" rid="CR32">32</xref>], anxiety [<xref ref-type="bibr" rid="CR33">33</xref>], health-related quality of life [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] and cognitive functioning [<xref ref-type="bibr" rid="CR36">36</xref>]. In addition, it will be investigated whether vitamin D supplementation is a cost-effective strategy for the above-mentioned aims. If proven effective, vitamin D supplementation can easily be implemented in the primary care setting as a simple and safe strategy to prevent both mental and physical disorders in the elderly population.</p></sec><sec id="Sec2"><title>Methods/design</title><sec id="Sec3"><title>Design of the study</title><p>The D-Vitaal study is a randomized, double-blind, placebo-controlled clinical trial that is carried out in the Netherlands. This study examines the effect of a daily dose of 1200&#x000a0;IU vitamin D<sub>3</sub> versus placebo on depressive symptoms, functional limitations and physical performance. We included 155 participants aged 60&#x02013;80 years. The duration of the intervention is one year. The D-Vitaal trial was approved by the Medical Ethics Committee of the VU University Medical Centre Amsterdam and is registered with the Netherlands Trial Register under <ext-link ext-link-type="uri" xlink:href="http://www.trialregistry.nl/NTR3845">NTR3845</ext-link>. The D-Vitaal study adheres to the CONSORT guidelines for randomized controlled trials.</p></sec><sec id="Sec4"><title>Participants</title><p>Potential participants were screened for presence of clinically relevant depressive symptoms, functional limitations and low serum 25(OH)D levels (&#x02264;50 or &#x02264;70&#x000a0;nmol/L in winter (October-March) and summer (April-September), respectively). In this way, we recruited a vulnerable population at high risk of subsequent mental and physical function decline. As severe 25(OH)D deficiency can be associated with bone disease [<xref ref-type="bibr" rid="CR37">37</xref>], persons with 25(OH)D levels of &#x0003c;15&#x000a0;nmol/L were excluded and referred to their GP for treatment. In addition, persons with a current MDD diagnosis were excluded, as the aim of this study is to prevent depression. Furthermore, persons who use antidepressant medication were excluded at screening because of possible interference of antidepressants with the effect of vitamin D on depressive symptoms. Persons with sufficient concentrations of 25(OH)D (&#x0003e;50 or &#x0003e;70&#x000a0;nmol/L in winter and summer, respectively) were also excluded, as it was expected that the effect of supplementation in these persons would be negligible. The summer/winter cut-off difference of 20&#x000a0;nmol/L was based on the observation by Van Schoor et al. that the seasonal variation of vitamin D levels in two cohorts of Dutch older persons was 14&#x02013;24&#x000a0;nmol/L [<xref ref-type="bibr" rid="CR38">38</xref>]. The Health Council of the Netherlands advises a supplement of 800&#x000a0;IU/day vitamin D for institutionalized persons [<xref ref-type="bibr" rid="CR39">39</xref>]. Therefore, only community dwelling persons were included in the trial. Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> lists the inclusion and exclusion criteria of the D-Vitaal study. All participants provided written informed consent prior to the start of the intervention.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Inclusion and exclusion criteria of the D-Vitaal study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inclusion criteria:</th><th>Exclusion criteria:</th></tr></thead><tbody><tr><td>- Men and women of &#x02265;60 and &#x02264;80&#x000a0;years</td><td>- Presence of major depressive disorder at&#x000a0;<break/>screening</td></tr><tr><td>- Presence of depressive symptoms (CES-D &#x02265;16)</td><td>- Use of antidepressant medication at screening</td></tr><tr><td>- Presence of &#x02265;1 functional limitation</td><td>- Presence of major life-threatening illness</td></tr><tr><td>- Serum 25(OH)D levels &#x02264;50 (winter) or &#x02264;70&#x000a0;<break/>(summer) nmol/L.</td><td>- Vitamin D (&#x0003e;400&#x000a0;IU/day) or calcium (&#x0003e;1000<break/>mg/day) supplementation</td></tr><tr><td>- Ability to comply with the study protocol</td><td>- Serum 25(OH)D levels &#x0003c;15&#x000a0;nmol/L.</td></tr><tr><td/><td>- Living in an institution</td></tr></tbody></table><table-wrap-foot><p>
<italic>CES-D</italic>: Centre of Epidemiological Studies Depression scale</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Recruitment and setting</title><p>The D-Vitaal study is carried out in Amsterdam and surrounding municipalities in the Netherlands. Both urban and rural areas were included. The majority of the participants was recruited through municipality registries. Municipalities in the surroundings of Amsterdam provided the addresses of inhabitants in the age range of 60&#x02013;80 years. These persons received an information brochure about the study by mail. In addition, advertisement posters and information leaflets were distributed in community centres. About 20&#x000a0;% of participants was recruited through general practitioners (GPs) in Amsterdam. Using a standardized search in their electronic medical records, the GPs selected eligible patients between 60&#x02013;80 years. These patients received a letter from their GP to draw their attention to the study. Finally, excluded participants of a previous clinical trial [<xref ref-type="bibr" rid="CR40">40</xref>] who had indicated to be interested in contributing to future research, were invited to participate in the D-Vitaal study. Recruitment commenced in June 2013 and the inclusion was finalized in April 2015. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows a flow chart of the recruitment, selection and randomization in the D-Vitaal study.<fig id="Fig2"><label>Fig. 2</label><caption><p>Recruitment, selection and randomization in the D-Vitaal study</p></caption><graphic xlink:href="12877_2015_148_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec6"><title>Screening phase</title><p>The screening phase of the D-Vitaal study included two steps: a mailed questionnaire and a short interview including a blood sample. The screening questionnaire assessed presence of depressive symptoms (Centre of Epidemiological Studies - Depression scale (CES-D) score of &#x02265;16 [<xref ref-type="bibr" rid="CR41">41</xref>]) and functional limitations and was also used to exclude persons who use antidepressant medication, vitamin D &#x0003e;400&#x000a0;IU/day and/or calcium supplements &#x0003e;1000&#x000a0;mg/day. For the first 12 participants, we used only the Functional Limitations questionnaire of the Longitudinal Aging Study Amsterdam (LASA-FL) [<xref ref-type="bibr" rid="CR42">42</xref>] for the assessment of functional limitations. A LASA-FL score of &#x02265;1 indicates the presence of functional limitations. However, this instrument proved not sensitive enough for this study population, creating a large ceiling effect. Especially younger-old participants (e.g. persons in their early sixties) reported few or no problems on this scale, as their level of general functioning was still moderate to high. Therefore, we added the Physical Functioning subscale of the Short Form-36 Health Survey [<xref ref-type="bibr" rid="CR43">43</xref>] (SF-36-PF) to the screening phase. The SF-36-PF contains 10 items on physical functioning and assesses a broader range of functional limitations. Having difficulty with at least one of the items of the SF-36-PF was regarded as presence of functional limitations. Persons who were eligible according to the screening questionnaire (presence of both depressive symptoms and functional limitations) were invited for a screening visit where presence of MDD was examined and a blood sample was drawn to determine serum 25(OH)D levels.</p></sec><sec id="Sec7"><title>Intervention and randomisation</title><p>Participants were randomly allocated with a 1:1 ratio to one of two treatment groups: vitamin D<sub>3</sub> (cholecalciferol) 1200&#x000a0;IU/day or placebo. Participants were stratified by sex and women were stratified by age (60&#x02013;70 years/71&#x02013;80 years). An independent pharmacist prepared three randomisation lists with computer-generated numbers using block sizes of four.</p><p>The intervention group takes three tablets of 400&#x000a0;IU vitamin D<sub>3</sub> daily for a duration of 12&#x000a0;months. Based on earlier research, the daily dose of 1200&#x000a0;IU will lead to stable mean 25(OH)D levels of &#x0003e;80&#x000a0;nmol/L in the intervention group, with 90&#x000a0;% of individual 25(OH)D levels above&#x000a0;60&#x000a0;nmol/L within a few months [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The placebo group receives identical tablets without vitamin D and it is expected that this group maintains a mean serum 25(OH)D level of about 45&#x000a0;nmol/L. Both the vitamin D and placebo tablets were purchased from Vemedia Manufacturing B.V., The Netherlands. The tablets are supplied in vials of 100 tablets for 6&#x000a0;months, 600 tablets at a time. Participants are allowed to take a (multi)vitamin D supplement with a maximum of 400&#x000a0;IU/day in addition to the study tablets.</p><sec id="Sec8"><title>Co-intervention</title><p>Calcium positively influences the bioavailability of vitamin D [<xref ref-type="bibr" rid="CR46">46</xref>]. In addition, some effects of vitamin D may be caused by increased calcium absorption. Therefore, all participants were advised to use at least three dairy consumptions daily to ensure adequate calcium intake of about 1000&#x000a0;mg/day. Calcium intake was assessed with a structured questionnaire during the screening phase. If calcium intake was low (less than 2 dairy consumptions per day), calcium tablets of 500&#x000a0;mg/day were prescribed to these participants.</p></sec></sec><sec id="Sec9"><title>Study procedures</title><p>Face-to-face interviews take place at screening, baseline, six and 12&#x000a0;months. The baseline visit was timed closely after the screening phase. Shortly prior to the interviews, participants are asked to complete a mailed questionnaire to reduce interview time. Short telephone interviews are conducted after two weeks, three and nine months to check compliance and adverse events. Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> lists all measurements and their time points of the D-Vitaal study. Interviews and blood sampling are carried out by trained researchers or research nurses and take place at the participant&#x02019;s home, at the VU University Medical Center, or at local community medical centres. The Endocrine Laboratory of the VU University Medical Center conducts the 25(OH)D determinations. Participants who discontinue taking the study tablets for any reason are asked to participate in the remaining follow-up measurements. Any (serious) adverse events are carefully monitored.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Assessed domains, instruments and their time points in the D-Vitaal study</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="4">
<italic>Time point</italic>
</th></tr><tr><th>Domain</th><th>Instrument</th><th>Screening</th><th>T0&#x000a0;<break/>(baseline)</th><th>T1&#x000a0;<break/>(6&#x000a0;months)</th><th>T2&#x000a0;<break/>(12&#x000a0;months)</th></tr></thead><tbody><tr><td colspan="6">Primary outcome variables:</td></tr><tr><td>Depressive symptoms</td><td>CES-D</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="2">Functional Limitations</td><td>LASA-FL</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>SF-36 PCS</td><td>Partly</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Physical performance</td><td>SPPB</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td colspan="6">Secondary outcome variables:</td></tr><tr><td>Major depressive disorder</td><td>CIDI</td><td>X</td><td/><td>X</td><td>X</td></tr><tr><td>Anxiety</td><td>BAI</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="2">Health-related quality of life</td><td>SF-36</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>EQ-5D</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Cognition</td><td>Stroop test</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td colspan="6">Physical performance</td></tr><tr><td>Mobility</td><td>TUG</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Hand grip strength</td><td>Dynamometer</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Health care costs</td><td>TiC-P</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Serum 25(OH)D</td><td/><td>X</td><td/><td>X</td><td/></tr><tr><td colspan="6">Possible covariables:</td></tr><tr><td>Demographic information</td><td/><td/><td/><td/><td/></tr><tr><td>Age, sex</td><td/><td>X</td><td/><td/><td/></tr><tr><td>Education level</td><td/><td/><td>X</td><td/><td/></tr><tr><td>Marital status</td><td/><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Lifestyle</td><td/><td/><td/><td/><td/></tr><tr><td>Smoking behaviour</td><td/><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Alcohol consumption</td><td/><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Physical activity</td><td>LAPAQ</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Blood pressure</td><td>Omron device</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Anthropometry</td><td/><td/><td/><td/><td/></tr><tr><td>BMI</td><td>Height, weight</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Waist and calf circumference</td><td>Tape measure</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Chronic diseases</td><td>7 majors</td><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Medication and supplement use</td><td/><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Predictors of vitamin D status</td><td/><td/><td>X</td><td>X</td><td>X</td></tr><tr><td>Use of counselling</td><td/><td/><td>X</td><td>X</td><td>X</td></tr></tbody></table><table-wrap-foot><p>CES-D: Centre of Epidemiological Studies Depression scale; LASA-FL: Longitudinal Aging Study Amsterdam Functional Limitations questionnaire; SF-36 PCS: Short Form 36 Health Survey - Physical Component Summary score; SPPB: Short Physical Performance Battery; CIDI: Composite International Diagnostic Interview; BAI: Beck Anxiety Inventory; EQ-5D: EuroQol 5 Dimensions; TUG: Timed Up-and-Go test; TiC-P: Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness; LAPAQ: Longitudinal Aging Study Amsterdam Physical Activity Questionnaire</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Compliance</title><p>Compliance is checked by tablet count. To stimulate compliance, participants are contacted by telephone (after two weeks, three and nine months) and reminded at follow-up visits. The ultimate compliance check is the measurement of serum 25(OH)D after 6&#x000a0;months.</p></sec><sec id="Sec11"><title>Outcomes</title><sec id="Sec12"><title>Primary outcomes</title><sec id="FPar1"><title>Depressive symptoms</title><p>The CES-D [<xref ref-type="bibr" rid="CR41">41</xref>] is used to measure differences in mean change of depressive symptoms after 12&#x000a0;months between the two treatment groups. The CES-D contains 20 items with a score range of 0&#x02013;60. Higher scores indicate more depressive symptoms. A score of &#x02265;16 is indicative of clinically relevant depressive symptoms. The CES-D is a widely used instrument that displays good psychometric properties in various elderly populations [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="FPar2"><title>Functional limitations</title><p>The LASA-FL questionnaire [<xref ref-type="bibr" rid="CR42">42</xref>] includes six items assessing common daily activities: climbing stairs, cutting toenails, walking 5&#x000a0;minutes outdoors without resting, rising from a chair, dressing/undressing oneself and using own or public transport. Participants indicate whether they are able to perform these activities without difficulty, with some difficulty, with much difficulty, only with help, or not at all. The instrument can be scored in two ways: by determining the amount of functional limitations (score range 0&#x02013;6, with higher scores indicating presence of more functional limitations) and the degree of functional limitations (score range 0&#x02013;24, with higher scores indicating more severe functional limitations). The LASA-FL is used to measure differences in mean change of the amount and degree of functional limitations after 12&#x000a0;months between the two treatment groups.</p></sec><sec id="FPar3"><title>Physical performance</title><p>A modified version of the Short Physical Performance Battery (SPPB) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] is used to determine differences in mean change of objective physical performance between the treatment groups after 12&#x000a0;months. The SPPB includes a walking test (walking 3 meters, turning 180&#x000b0; and walking 3 meters back as fast as possible), a chair stands test (standing up from a chair without using hands five times as fast as possible) and a balance test (standing with feet in tandem stand (i.e. standing with one foot in front of the other, with the heel of one foot touching the toes of the other foot) for up to 30&#x000a0;seconds). Participants can score 0&#x02013;4 points for each test, adding up to a maximum of 12 points, with higher scores indicating better performance. Reliability and validity of the SPPB are good [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec></sec><sec id="Sec13"><title>Secondary outcomes</title><sec id="FPar4"><title>Incidence of MDD</title><p>The depression-section of the DSM IV-based Composite International Diagnostic Interview (CIDI, version 2.1) [<xref ref-type="bibr" rid="CR50">50</xref>] is used to assess presence of MDD. At six and 12&#x000a0;months, the CIDI is administered if a participant scores &#x02265;16 on the CES-D.</p></sec><sec id="FPar5"><title>Anxiety</title><p>The Beck Anxiety Index (BAI) [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>] is a well-validated questionnaire that contains 21 items measuring anxiety symptoms that are relatively distinguishable from depression symptoms.</p></sec><sec id="FPar6"><title>Cognition</title><p>Cognitive function is assessed with indicators of information processing speed and executive functioning obtained from the Stroop-Colour Word Test [<xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="FPar7"><title>Health-related quality of life</title><p>Health-related quality of life is measured with the EuroQol - 5 Dimensions (EQ-5D) [<xref ref-type="bibr" rid="CR54">54</xref>] and the SF-36 [<xref ref-type="bibr" rid="CR43">43</xref>]. The EQ-5D is a utility instrument that enables the calculation of Quality Adjusted Life Years (QALY&#x02019;s). The SF-36 Mental Component Summary score (MCS) and Physical Component Summary score (PCS) are used as a measure of mental and physical health-related quality of life, respectively [<xref ref-type="bibr" rid="CR43">43</xref>]. Both instruments are widely used and well-validated in older populations [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p></sec><sec id="FPar8"><title>Timed Up-and-Go test</title><p>With the Timed Up-And-Go Test (TUG), functional mobility is assessed by asking the participant to stand up from a standard chair, walk a 3 meter distance, turn, walk back to the chair and sit down again [<xref ref-type="bibr" rid="CR56">56</xref>].</p></sec><sec id="FPar9"><title>Hand grip strength</title><p>Hand grip strength is measured in kilograms with a strain-gauged dynamometer (Takei TKK 5401, Takei Scientific Instruments Co. Ltd., Japan). Participants are asked to apply maximum force on the device while in a standing position. Grip strength is measured twice for each hand, consecutively alternating between both hands. The hand grip strength score is derived by taking the mean of the highest score for each hand.</p></sec><sec id="FPar10"><title>Economic evaluation</title><p>To evaluate whether vitamin D is a cost-effective intervention for the prevention of depression and poor physical function in older persons, an economic evaluation will be performed. Dutch costing guidelines will be used [<xref ref-type="bibr" rid="CR57">57</xref>]. All relevant costs will be measured and valued, including the costs of the vitamin D intervention. Health care utilization is measured with the Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TiC-P) [<xref ref-type="bibr" rid="CR58">58</xref>]. Health care costs include costs of GP and psychiatric care, ambulatory and outpatient hospital care, physical therapists and home care. Costs of production loss are not included, as the majority of the participants does not have a paid job.</p></sec></sec><sec id="Sec14"><title>Possible covariables</title><p>Several variables are measured during the trial to check for possible (chance-based) differences between the treatment groups. Height and weight are measured with a calibrated stadiometer and scale, respectively. Body mass index (BMI) is calculated by dividing weight (in kilograms) by height<sup>2</sup> (in meters). Waist and calf circumference is assessed with a tape-measure. Blood pressure and pulse are assessed twice with a three-minute interval using the Omron M1 Plus device (Omron Healthcare Europe). The date of the baseline interview is used to measure seasonal variation of serum 25(OH)D levels [<xref ref-type="bibr" rid="CR38">38</xref>]. Structured questionnaires assess age, gender, education level, marital status, smoking behaviour, alcohol use, current medication and supplement use, use of corticosteroids in the past three months, chronic diseases, physical activity (walking, cycling, gardening, household activities and sports [<xref ref-type="bibr" rid="CR59">59</xref>], vitamin D predictors (exposure to sunlight, skin pigmentation, consumption of fatty fish) [<xref ref-type="bibr" rid="CR60">60</xref>] and use of counselling.</p></sec><sec id="Sec15"><title>Blood sampling and assessment of serum 25(OH)D</title><p>Blood samples are obtained in the morning by a trained research nurse at screening and 6&#x000a0;months for measurement of serum 25(OH)D. Participants are in a fasted state with regard to dairy products. Serum 25(OH)D is determined using liquid chromatography followed by tandem mass spectrometry [<xref ref-type="bibr" rid="CR61">61</xref>]. At screening, 25(OH)D was determined immediately after blood sampling. The 25(OH)D determinations of the 6-month blood samples will be carried out at the end of the study, to ensure randomization concealment. Serum, EDTA plasma and whole blood samples are stored frozen (&#x02212;80&#x000a0;&#x000b0; C) until determination and for potential future biomarker and DNA research.</p></sec></sec><sec id="Sec16"><title>Power calculation</title><p>The primary outcomes of the D-Vitaal study are change in depressive symptoms (CES-D score) and change in physical functioning (functional limitations and physical performance) after 12&#x000a0;months. In an RCT with a comparable population (older persons from the community with depressive symptoms but no MDD), the mean CES-D score was 26 (SD: 5.1) [<xref ref-type="bibr" rid="CR62">62</xref>]. To detect a change of 0.5 SD (i.e. 2.5 points change of CES-D score), a total of 40 subjects per group is needed, assuming a power of 80&#x000a0;%, a two-sided alpha of .05 and an intraclass correlation coefficient (ICC) of .70 between baseline and follow-up measurements.</p><p>The SPPB score ranges from 0 to 12. A change of one point (SD: 1.5) is regarded as a meaningful change [<xref ref-type="bibr" rid="CR63">63</xref>]. Assuming the same power, alpha and ICC as the CES-D calculation, 22 participants per group are needed.</p><p>The LASA-FL questionnaire is scored in two ways: by determining the amount (score range 0&#x02013;6) and the degree (score range 0&#x02013;24) of functional limitations. A change of one point in the amount of functional limitations can be regarded as a meaningful change [<xref ref-type="bibr" rid="CR64">64</xref>]. The SD was set on 1.7, based on analyses in the Longitudinal Aging Study Amsterdam (LASA), a large prospective cohort study of older persons. Assuming again the same power, alpha and ICC as the previous calculations, at least 28 persons per group should be included. For the degree of functional limitations, no meaningful change data or RCTs could be identified in the literature. Based on analyses in LASA, a mean difference of 2 points can be expected, with an SD of 4.5. For this outcome, 48 persons per group are needed, using the same assumptions as indicated above. Considering an expected dropout of 25&#x000a0;% and uncertainty of the 25(OH)D assay, we aimed to include at least 70 participants per group, altogether at least 140 participants.</p></sec><sec id="Sec17"><title>Data analysis</title><p>Baseline characteristics between treatment groups will be compared using Pearson Chi-square tests, independent-samples t-tests, one-way ANOVAs, or non-parametric tests. Persons who drop out will be compared to persons who complete the study. Skewed data will be transformed. Data will be analysed according to the intention-to-treat principle with longitudinal data analysis techniques (generalized estimating equation (GEE) analysis or mixed model analysis) using SPSS (SPSS Inc. Chicago, IL, USA). A double-sided <italic>p</italic>-value of .05 will be regarded as statistically significant. If needed, models will be adjusted for relevant confounding variables. To investigate the interrelatedness of depressive symptoms and physical functioning, these variables will be added to each other&#x02019;s effect analysis in separate models. Effect modification will be investigated for age, gender and baseline serum 25(OH)D levels.</p><p>Per-protocol analyses will be performed as a secondary analysis with participants who were compliant with the study protocol (&#x02265;80&#x000a0;% tablet intake). As a compliance check, the improvement of vitamin D status - i.e. the number of participants with serum 25(OH)D levels over 50, 60 and 75&#x000a0;nmol/L - will also be analysed in secondary analyses. Finally, as a sensitivity analysis, it will be investigated whether change in serum 25(OH)D is associated with change in depressive symptoms, functional limitations and physical performance over time in the total study sample (irrespective of treatment group).</p><p>The economic evaluation will be performed from a societal perspective with a time horizon of 12&#x000a0;months. The analysis will be done according to the intention-to-treat principle. Missing cost and effect data will be imputed using multiple imputation according to the MICE algorithm [<xref ref-type="bibr" rid="CR65">65</xref>]. Bias-corrected and accelerated bootstrapping with 5000 replications will be used to calculate 95&#x000a0;% confidence intervals around the mean difference in total costs between the two groups. Incremental cost-effectiveness ratios (ICERs) will be calculated by dividing the difference in mean total costs by the difference in mean effects on the primary outcomes (depressive symptoms, functional limitations and physical performance) between the treatment groups. A cost-utility analysis will be performed estimating the incremental costs per QALY gained. Bootstrapping will be used to estimate the uncertainty surrounding the ICERs, which will be graphically presented on cost-effectiveness planes. Cost-effectiveness acceptability curves and net monetary benefits will also be calculated. Sensitivity analyses will be performed on the most important and uncertain cost parameters.</p></sec></sec><sec id="Sec18" sec-type="discussion"><title>Discussion</title><p>As depressive symptoms and poor physical functioning are prevalent among older persons and cause significant individual and societal burden [<xref ref-type="bibr" rid="CR66">66</xref>], effective low-cost prevention strategies are urgently needed. The D-Vitaal study aims to examine whether vitamin D supplementation decreases depressive symptoms and functional limitations and improves physical performance in older adults. The majority of RCTs that examined vitamin D supplementation included participants with adequate serum 25(OH)D levels and good mental and physical health, which may explain the absence of effects of some previous clinical trials in the field [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>The D-Vitaal trial is innovative in several ways: it includes persons who may benefit most from the supplementation: older persons with low serum 25(OH)D levels and at high risk for developing poor mental and physical health. Furthermore, the tight interrelationship between depressive symptoms and physical functioning is taken into account by targeting both concepts in one RCT. Physical functioning is measured comprehensively with both self-reported questionnaires and objective tests. Finally, MDD diagnosis is included as a secondary outcome measure. This enables us to explore the effect of the vitamin D supplementation on the development of MDD. To our knowledge, this outcome has not been investigated previously in an RCT [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>It is more urgent to study the effects of vitamin D supplementation in persons with inadequate vitamin D levels than to examine whether there are any additional effects of supplementation above normal ranges [<xref ref-type="bibr" rid="CR67">67</xref>]. The amount of supplementation (1200&#x000a0;IU/ day) used in the D-Vitaal study is a moderate dose, but sufficient to correct for deficiency and obtain an adequate vitamin D status [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>].</p><p>If the results of the D-Vitaal trial indicate that vitamin D supplementation is effective in reducing depressive symptoms and improving physical functioning in older adults, vitamin D can be an efficient intervention that targets two prevalent adverse health conditions simultaneously. The economic evaluation will provide evidence on the cost-effectiveness of the intervention. As vitamin D supplementation is inexpensive and displays minimal side effects, opportunities for implementation in the primary care setting seem promising. The first results of the D-Vitaal study are expected in 2016.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>1,25(OH)<sub>2</sub>D</term><def><p>1,25 dihydroxyvitamin D</p></def></def-item><def-item><term>25(OH)D</term><def><p>25 hydroxyvitamin D</p></def></def-item><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>BAI</term><def><p>Beck Anxiety Inventory</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>CES-D</term><def><p>Centre of Epidemiological Studies - Depression scale</p></def></def-item><def-item><term>CIDI</term><def><p>Composite International Diagnostic Interview</p></def></def-item><def-item><term>DSM</term><def><p>Diagnostic and Statistical Manual of Mental Disorders</p></def></def-item><def-item><term>EQ-5D</term><def><p>EuroQol-5 Dimensions</p></def></def-item><def-item><term>EQ-VAS</term><def><p>EuroQol Visual Analog Scale</p></def></def-item><def-item><term>GEE</term><def><p>generalized estimating equations</p></def></def-item><def-item><term>GP</term><def><p>general practitioner</p></def></def-item><def-item><term>ICC</term><def><p>intraclass correlation coefficient</p></def></def-item><def-item><term>ICER</term><def><p>incremental cost-effectiveness ratios</p></def></def-item><def-item><term>LASA-FL</term><def><p>Longitudinal Aging Study Amsterdam Functional Limitations questionnaire</p></def></def-item><def-item><term>MCS</term><def><p>Mental Component Summary (SF-36)</p></def></def-item><def-item><term>MDD</term><def><p>major depressive disorder</p></def></def-item><def-item><term>PCS</term><def><p>Physical Component Summary score (SF-36)</p></def></def-item><def-item><term>QALY</term><def><p>quality-adjusted life year</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term>SF-36</term><def><p>Short Form-36 Health Survey</p></def></def-item><def-item><term>SPPB</term><def><p>Short Physical Performance Battery</p></def></def-item><def-item><term>TiC-P</term><def><p>Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness</p></def></def-item><def-item><term>TUG test</term><def><p>Timed Up-and-Go test</p></def></def-item><def-item><term>VDR</term><def><p>vitamin D receptor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>NMvS and PL primarily designed the D-Vitaal study, all other authors contributed to the design; PL is the principal investigator; NMvS is the trial coordinator; EJdK, NMvS, HWJvM, BWJHP, PJME and PL conduct the research, ACH coordinates the serum 25(OH)D determinations from blood samples; PMB coordinates the issuing of the study tablets; MWvT designed the economic evaluation study; MdH and JHS assist with the statistical analyses, EJdK collects the data (together with the research assistants) and drafted the manuscript; all authors provided critical revision of the manuscript and approved the final version.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are very grateful to all participants of the D-Vitaal study for their valued contributions. We would like to thank all general practitioners and municipalities that helped us with the recruitment of participants. Furthermore, we thank our research assistants Ans Nicolaas and Nicolette Pliester for their dedicated work and all students and colleagues involved in the D-Vitaal study for their most-appreciated assistance.</p><p>The D-Vitaal study is funded by The Netherlands Organization for Health Research and Development (ZonMw), the Hague, the Netherlands (grant number 200210022). ZonMw had no role in the design of the study, the collection, analysis and interpretation of the data, or in the preparation, review, or approval of the manuscript.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blazer</surname><given-names>DG</given-names></name></person-group><article-title>Depression in late life: review and commentary</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2003</year><volume>58</volume><fpage>249</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1093/gerona/58.3.M249</pub-id><pub-id pub-id-type="pmid">12634292</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>CA</given-names></name><name><surname>Reynolds-Iii</surname><given-names>CF</given-names></name></person-group><article-title>Late-life depression in the primary care setting: challenges, collaborative care, and prevention</article-title><source>Maturitas</source><year>2014</year><volume>79</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2014.05.026</pub-id><pub-id pub-id-type="pmid">24996484</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prina</surname><given-names>AM</given-names></name><name><surname>Deeg</surname><given-names>D</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Beekman</surname><given-names>A</given-names></name><name><surname>Huisman</surname><given-names>M</given-names></name></person-group><article-title>The association between depressive symptoms and non-psychiatric hospitalisation in older adults</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0034821</pub-id><pub-id pub-id-type="pmid">22496867</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>MA</given-names></name><name><surname>Verhaak</surname><given-names>PFM</given-names></name><name><surname>Hilbink-Smolders</surname><given-names>M</given-names></name><name><surname>Spreeuwenberg</surname><given-names>P</given-names></name><name><surname>Laurant</surname><given-names>MGH</given-names></name><name><surname>van der Meer</surname><given-names>K</given-names></name><etal/></person-group><article-title>Outcomes for depression and anxiety in primary care and details of treatment: a naturalistic longitudinal study</article-title><source>BMC Psychiatry</source><year>2011</year><volume>11</volume><fpage>180</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-11-180</pub-id><pub-id pub-id-type="pmid">22099636</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braam</surname><given-names>AW</given-names></name><name><surname>Prince</surname><given-names>MJ</given-names></name><name><surname>Beekman</surname><given-names>ATF</given-names></name><name><surname>Delespaul</surname><given-names>P</given-names></name><name><surname>Dewey</surname><given-names>ME</given-names></name><name><surname>Geerlings</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Physical health and depressive symptoms in older Europeans. Results from EURODEP</article-title><source>Br J Psychiatry</source><year>2005</year><volume>187</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1192/bjp.187.1.35</pub-id><pub-id pub-id-type="pmid">15994569</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bromberger</surname><given-names>JT</given-names></name><name><surname>di Scalea</surname><given-names>TL</given-names></name></person-group><article-title>Longitudinal associations between depression and functioning in midlife women</article-title><source>Maturitas</source><year>2009</year><volume>64</volume><fpage>145</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2009.09.017</pub-id><pub-id pub-id-type="pmid">19854010</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Deeg</surname><given-names>DJ</given-names></name><name><surname>van Eijk</surname><given-names>JT</given-names></name><name><surname>Beekman</surname><given-names>AT</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name></person-group><article-title>Changes in depression and physical decline in older adults: a longitudinal perspective</article-title><source>J Affect Disord</source><year>2000</year><volume>61</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0165-0327(00)00152-X</pub-id><pub-id pub-id-type="pmid">11099735</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vink</surname><given-names>D</given-names></name><name><surname>Aartsen</surname><given-names>MJ</given-names></name><name><surname>Schoevers</surname><given-names>RA</given-names></name></person-group><article-title>Risk factors for anxiety and depression in the elderly: a review</article-title><source>J Affect Disord</source><year>2008</year><volume>106</volume><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2007.06.005</pub-id><pub-id pub-id-type="pmid">17707515</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyunt</surname><given-names>MSZ</given-names></name><name><surname>Lim</surname><given-names>ML</given-names></name><name><surname>Yap</surname><given-names>KB</given-names></name><name><surname>Ng</surname><given-names>TP</given-names></name></person-group><article-title>Changes in depressive symptoms and functional disability among community-dwelling depressive older adults</article-title><source>Int Psychogeriatr</source><year>2012</year><volume>24</volume><fpage>1633</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1017/S1041610212000890</pub-id><pub-id pub-id-type="pmid">22613130</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaudart</surname><given-names>C</given-names></name><name><surname>Buckinx</surname><given-names>F</given-names></name><name><surname>Rabenda</surname><given-names>V</given-names></name><name><surname>Gillain</surname><given-names>S</given-names></name><name><surname>Cavalier</surname><given-names>E</given-names></name><name><surname>Slomian</surname><given-names>J</given-names></name><etal/></person-group><article-title>The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials</article-title><source>J Clin Endocrinol Metab</source><year>2014</year><volume>99</volume><fpage>4336</fpage><lpage>4345</lpage><pub-id pub-id-type="doi">10.1210/jc.2014-1742</pub-id><pub-id pub-id-type="pmid">25033068</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowda</surname><given-names>U</given-names></name><name><surname>Mutowo</surname><given-names>MP</given-names></name><name><surname>Smith</surname><given-names>BJ</given-names></name><name><surname>Wluka</surname><given-names>AE</given-names></name><name><surname>Renzaho</surname><given-names>AMN</given-names></name></person-group><article-title>Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials</article-title><source>Nutrition</source><year>2015</year><volume>31</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2014.06.017</pub-id><pub-id pub-id-type="pmid">25701329</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaffer</surname><given-names>JA</given-names></name><name><surname>Edmondson</surname><given-names>D</given-names></name><name><surname>Wasson</surname><given-names>LT</given-names></name><name><surname>Falzon</surname><given-names>L</given-names></name><name><surname>Homma</surname><given-names>K</given-names></name><name><surname>Ezeokoli</surname><given-names>N</given-names></name><etal/></person-group><article-title>Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Psychosom Med</source><year>2014</year><volume>76</volume><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1097/PSY.0000000000000044</pub-id><pub-id pub-id-type="pmid">24632894</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>IOM (Institute of Medicine)</collab></person-group><source>Dietary reference intakes for calcium and vitamin D</source><year>2011</year><publisher-loc>Washington DC</publisher-loc><publisher-name>The National Academies Press</publisher-name></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuchuk</surname><given-names>NO</given-names></name><name><surname>Pluijm</surname><given-names>SMF</given-names></name><name><surname>van Schoor</surname><given-names>NM</given-names></name><name><surname>Looman</surname><given-names>CWN</given-names></name><name><surname>Smit</surname><given-names>JH</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><fpage>1244</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-1832</pub-id><pub-id pub-id-type="pmid">19158198</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>van Schoor</surname><given-names>NM</given-names></name><name><surname>de Jongh</surname><given-names>RT</given-names></name></person-group><article-title>Diet, sun, and lifestyle as determinants of vitamin D status</article-title><source>Ann N Y Acad Sci</source><year>2014</year><volume>1317</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1111/nyas.12443</pub-id><pub-id pub-id-type="pmid">24814938</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Vitamin D, deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications</article-title><source>Endocr Rev</source><year>2001</year><volume>22</volume><fpage>477</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1210/edrv.22.4.0437</pub-id><pub-id pub-id-type="pmid">11493580</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Abreu DA</surname><given-names>F</given-names></name><name><surname>Eyles</surname><given-names>D</given-names></name><name><surname>Feron</surname><given-names>F</given-names></name></person-group><article-title>Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases</article-title><source>Psychoneuroendocrinology</source><year>2009</year><volume>34</volume><issue>1</issue><fpage>S265</fpage><lpage>S277</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2009.05.023</pub-id><pub-id pub-id-type="pmid">19545951</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyles</surname><given-names>DW</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Kinobe</surname><given-names>R</given-names></name><name><surname>Hewison</surname><given-names>M</given-names></name><name><surname>McGrath</surname><given-names>JJ</given-names></name></person-group><article-title>Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain</article-title><source>J Chem Neuroanat</source><year>2005</year><volume>29</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2004.08.006</pub-id><pub-id pub-id-type="pmid">15589699</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annweiler</surname><given-names>C</given-names></name><name><surname>Montero-Odasso</surname><given-names>M</given-names></name><name><surname>Schott</surname><given-names>AM</given-names></name><name><surname>Berrut</surname><given-names>G</given-names></name><name><surname>Fantino</surname><given-names>B</given-names></name><name><surname>Beauchet</surname><given-names>O</given-names></name></person-group><article-title>Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects</article-title><source>J Neuroeng Rehabil</source><year>2010</year><volume>7</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/1743-0003-7-50</pub-id><pub-id pub-id-type="pmid">20937091</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesby</surname><given-names>JP</given-names></name><name><surname>Eyles</surname><given-names>DW</given-names></name><name><surname>Burne</surname><given-names>THJ</given-names></name><name><surname>McGrath</surname><given-names>JJ</given-names></name></person-group><article-title>The effects of vitamin D on brain development and adult brain function</article-title><source>Mol Cell Endocrinol</source><year>2011</year><volume>347</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2011.05.014</pub-id><pub-id pub-id-type="pmid">21664231</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyles</surname><given-names>DW</given-names></name><name><surname>Burne</surname><given-names>THJ</given-names></name><name><surname>McGrath</surname><given-names>JJ</given-names></name></person-group><article-title>Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease</article-title><source>Front Neuroendocrinol</source><year>2013</year><volume>34</volume><fpage>47</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.yfrne.2012.07.001</pub-id><pub-id pub-id-type="pmid">22796576</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtzer</surname><given-names>R</given-names></name><name><surname>Epstein</surname><given-names>N</given-names></name><name><surname>Mahoney</surname><given-names>JR</given-names></name><name><surname>Izzetoglu</surname><given-names>M</given-names></name><name><surname>Blumen</surname><given-names>HM</given-names></name></person-group><article-title>Neuroimaging of mobility in aging: a targeted review</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2014</year><volume>69</volume><fpage>1375</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1093/gerona/glu052</pub-id><pub-id pub-id-type="pmid">24739495</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogendijk</surname><given-names>WJG</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>Dik</surname><given-names>MG</given-names></name><name><surname>Deeg</surname><given-names>DJH</given-names></name><name><surname>Beekman</surname><given-names>ATF</given-names></name><name><surname>Penninx</surname><given-names>BWJH</given-names></name></person-group><article-title>Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults</article-title><source>Arch Gen Psychiatry</source><year>2008</year><volume>65</volume><fpage>508</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.65.5.508</pub-id><pub-id pub-id-type="pmid">18458202</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milaneschi</surname><given-names>Y</given-names></name><name><surname>Hoogendijk</surname><given-names>W</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>Heijboer</surname><given-names>AC</given-names></name><name><surname>Schoevers</surname><given-names>R</given-names></name><name><surname>van Hemert</surname><given-names>AM</given-names></name><etal/></person-group><article-title>The association between low vitamin D and depressive disorders</article-title><source>Mol Psychiatry</source><year>2014</year><volume>19</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/mp.2013.36</pub-id><pub-id pub-id-type="pmid">23568194</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohl</surname><given-names>E</given-names></name><name><surname>de Jongh</surname><given-names>RT</given-names></name><name><surname>Heijboer</surname><given-names>AC</given-names></name><name><surname>Swart</surname><given-names>KMA</given-names></name><name><surname>Brouwer-Brolsma</surname><given-names>EM</given-names></name><name><surname>Enneman</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Vitamin D status is associated with physical performance: the results of three independent cohorts</article-title><source>Osteoporos Int</source><year>2013</year><volume>24</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1007/s00198-012-2124-5</pub-id><pub-id pub-id-type="pmid">22961566</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wicherts</surname><given-names>IS</given-names></name><name><surname>van Schoor</surname><given-names>NM</given-names></name><name><surname>Boeke</surname><given-names>AJ</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Deeg</surname><given-names>DJH</given-names></name><name><surname>Smit</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vitamin D status predicts physical performance and its decline in older persons</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>2058</fpage><lpage>2065</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-1525</pub-id><pub-id pub-id-type="pmid">17341569</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milaneschi</surname><given-names>Y</given-names></name><name><surname>Shardell</surname><given-names>M</given-names></name><name><surname>Corsi</surname><given-names>AM</given-names></name><name><surname>Vazzana</surname><given-names>R</given-names></name><name><surname>Bandinelli</surname><given-names>S</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Serum 25-hydroxyvitamin D and depressive symptoms in older women and men</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><fpage>3225</fpage><lpage>3233</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-0347</pub-id><pub-id pub-id-type="pmid">20444911</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoraminya</surname><given-names>N</given-names></name><name><surname>Tehrani-Doost</surname><given-names>M</given-names></name><name><surname>Jazayeri</surname><given-names>S</given-names></name><name><surname>Hosseini</surname><given-names>A</given-names></name><name><surname>Djazayery</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder</article-title><source>Aust N Z J Psychiatry</source><year>2013</year><volume>47</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1177/0004867412465022</pub-id><pub-id pub-id-type="pmid">23093054</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaergaard</surname><given-names>M</given-names></name><name><surname>Waterloo</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>CEA</given-names></name><name><surname>Almas</surname><given-names>B</given-names></name><name><surname>Figenschau</surname><given-names>Y</given-names></name><name><surname>Hutchinson</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case&#x02013;control study and randomised clinical trial</article-title><source>Br J Psychiatry</source><year>2012</year><volume>201</volume><fpage>360</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.111.104349</pub-id><pub-id pub-id-type="pmid">22790678</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffari-Khosravi</surname><given-names>H</given-names></name><name><surname>Nabizade</surname><given-names>L</given-names></name><name><surname>Yassini-Ardakani</surname><given-names>SM</given-names></name><name><surname>Hadinedoushan</surname><given-names>H</given-names></name><name><surname>Barzegar</surname><given-names>K</given-names></name></person-group><article-title>The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency: a randomized clinical trial</article-title><source>J Clin Psychopharmacol</source><year>2013</year><volume>33</volume><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e31828f619a</pub-id><pub-id pub-id-type="pmid">23609390</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhesi</surname><given-names>JK</given-names></name><name><surname>Jackson</surname><given-names>SHD</given-names></name><name><surname>Bearne</surname><given-names>LM</given-names></name><name><surname>Moniz</surname><given-names>C</given-names></name><name><surname>Hurley</surname><given-names>MV</given-names></name><name><surname>Swift</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Vitamin D supplementation improves neuromuscular function in older people who fall</article-title><source>Age Ageing</source><year>2004</year><volume>33</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/ageing/afh209</pub-id><pub-id pub-id-type="pmid">15501836</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JA</given-names></name><name><surname>Sink</surname><given-names>KM</given-names></name><name><surname>Tooze</surname><given-names>JA</given-names></name><name><surname>Atkinson</surname><given-names>HH</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name><etal/></person-group><article-title>Low 25-hydroxyvitamin D concentrations predict incident depression in well-functioning older adults: the health, aging, and body composition study</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2015</year><volume>70</volume><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1093/gerona/glu184</pub-id><pub-id pub-id-type="pmid">25326643</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>DJ</given-names></name><name><surname>Meenagh</surname><given-names>GK</given-names></name><name><surname>Bickle</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>ASH</given-names></name><name><surname>Curran</surname><given-names>ES</given-names></name><name><surname>Finch</surname><given-names>MB</given-names></name></person-group><article-title>Vitamin D deficiency is associated with anxiety and depression in fibromyalgia</article-title><source>Clin Rheumatol</source><year>2007</year><volume>26</volume><fpage>551</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1007/s10067-006-0348-5</pub-id><pub-id pub-id-type="pmid">16850115</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motsinger</surname><given-names>S</given-names></name><name><surname>Lazovich</surname><given-names>D</given-names></name><name><surname>MacLehose</surname><given-names>RF</given-names></name><name><surname>Torkelson</surname><given-names>CJ</given-names></name><name><surname>Robien</surname><given-names>K</given-names></name></person-group><article-title>Vitamin D intake and mental health-related quality of life in older women: the Iowa Women's Health Study</article-title><source>Maturitas</source><year>2012</year><volume>71</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2011.12.005</pub-id><pub-id pub-id-type="pmid">22209201</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakalli</surname><given-names>H</given-names></name><name><surname>Arslan</surname><given-names>D</given-names></name><name><surname>Yucel</surname><given-names>AE</given-names></name></person-group><article-title>The effect of oral and parenteral vitamin D supplementation in the elderly: a prospective, double-blinded, randomized, placebo-controlled study</article-title><source>Rheumatol Int</source><year>2012</year><volume>32</volume><fpage>2279</fpage><lpage>2283</lpage><pub-id pub-id-type="doi">10.1007/s00296-011-1943-6</pub-id><pub-id pub-id-type="pmid">21556746</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlogl</surname><given-names>M</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><article-title>Vitamin D and neurocognitive function</article-title><source>Clin Interv Aging</source><year>2014</year><volume>9</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">24729696</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Need</surname><given-names>AG</given-names></name><name><surname>O'Loughlin</surname><given-names>PD</given-names></name><name><surname>Morris</surname><given-names>HA</given-names></name><name><surname>Coates</surname><given-names>PS</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Nordin</surname><given-names>BEC</given-names></name></person-group><article-title>Vitamin D metabolites and calcium absorption in severe vitamin D deficiency</article-title><source>J Bone Miner Res</source><year>2008</year><volume>23</volume><fpage>1859</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1359/jbmr.080607</pub-id><pub-id pub-id-type="pmid">18597633</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Schoor</surname><given-names>NM</given-names></name><name><surname>Knol</surname><given-names>DL</given-names></name><name><surname>Deeg</surname><given-names>DJH</given-names></name><name><surname>Peters</surname><given-names>FPAM</given-names></name><name><surname>Heijboer</surname><given-names>AC</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Longitudinal changes and seasonal variations in serum 25-hydroxyvitamin D levels in different age groups: results of the Longitudinal Aging Study Amsterdam</article-title><source>Osteoporos Int</source><year>2014</year><volume>25</volume><fpage>1483</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">24570295</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Gezondheidsraad (Health Council of the Netherlands). Evaluatie van de voedingsnormen voor vitamine D (Evaluation of the dieatary reference values for vitamin D). <ext-link ext-link-type="uri" xlink:href="http://www.gezondheidsraad.nl/nl/taak-werkwijze/werkterrein/gezonde-voeding/evaluatie-van-devoedingsnormen-voor-vitamine-d.">http://www.gezondheidsraad.nl/nl/taak-werkwijze/werkterrein/gezonde-voeding/evaluatie-van-devoedingsnormen-voor-vitamine-d.</ext-link> (2008). Accessed 9 Nov, 2012.</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Wijngaarden</surname><given-names>JP</given-names></name><name><surname>Swart</surname><given-names>KMA</given-names></name><name><surname>Enneman</surname><given-names>AW</given-names></name><name><surname>Dhonukshe-Rutten</surname><given-names>RAM</given-names></name><name><surname>van Dijk</surname><given-names>SC</given-names></name><name><surname>Ham</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial</article-title><source>Am J Clin Nutr</source><year>2014</year><volume>100</volume><fpage>1578</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.3945/ajcn.114.090043</pub-id><pub-id pub-id-type="pmid">25411293</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radloff</surname><given-names>LS</given-names></name></person-group><article-title>The CES-D scale: a self-report depression scale for research in the general population</article-title><source>Appl Psychol Meas</source><year>1977</year><volume>1</volume><fpage>385</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1177/014662167700100306</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisschop</surname><given-names>MI</given-names></name><name><surname>Kriegsman</surname><given-names>DMW</given-names></name><name><surname>van Tilburg</surname><given-names>TG</given-names></name><name><surname>Penninx</surname><given-names>BWJH</given-names></name><name><surname>van Eijk</surname><given-names>JT</given-names></name><name><surname>Deeg</surname><given-names>DJH</given-names></name></person-group><article-title>The influence of differing social ties on decline in physical functioning among older people with and without chronic diseases: the Longitudinal Aging Study Amsterdam</article-title><source>Aging Clin Exp Res</source><year>2003</year><volume>15</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1007/BF03324496</pub-id><pub-id pub-id-type="pmid">12889849</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JEJ</given-names></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group><article-title>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</article-title><source>Med Care</source><year>1992</year><volume>30</volume><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1097/00005650-199206000-00002</pub-id><pub-id pub-id-type="pmid">1593914</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chel</surname><given-names>V</given-names></name><name><surname>Wijnhoven</surname><given-names>HAH</given-names></name><name><surname>Smit</surname><given-names>JH</given-names></name><name><surname>Ooms</surname><given-names>M</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents</article-title><source>Osteoporos Int</source><year>2008</year><volume>19</volume><fpage>663</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1007/s00198-007-0465-2</pub-id><pub-id pub-id-type="pmid">17874029</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>Wiersinga</surname><given-names>A</given-names></name><name><surname>van Ginkel</surname><given-names>FC</given-names></name><name><surname>Jongen</surname><given-names>MJ</given-names></name><name><surname>Netelenbos</surname><given-names>JC</given-names></name><name><surname>Hackeng</surname><given-names>WH</given-names></name><etal/></person-group><article-title>The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects</article-title><source>J Clin Endocrinol Metab</source><year>1988</year><volume>67</volume><fpage>644</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1210/jcem-67-4-644</pub-id><pub-id pub-id-type="pmid">3417845</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Interaction between vitamin D and calcium</article-title><source>Scand J Clin Lab Invest Suppl</source><year>2012</year><volume>243</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">22536764</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Rest</surname><given-names>O</given-names></name><name><surname>van der Zwaluw</surname><given-names>N</given-names></name><name><surname>Beekman</surname><given-names>ATF</given-names></name><name><surname>de Groot</surname><given-names>LCPG</given-names></name><name><surname>Geleijnse</surname><given-names>JM</given-names></name></person-group><article-title>The reliability of three depression rating scales in a general population of Dutch older persons</article-title><source>Int J Geriatr Psychiatry</source><year>2010</year><volume>25</volume><fpage>998</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1002/gps.2449</pub-id><pub-id pub-id-type="pmid">19998315</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Simonsick</surname><given-names>EM</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>Berkman</surname><given-names>LF</given-names></name><name><surname>Blazer</surname><given-names>DG</given-names></name><etal/></person-group><article-title>A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission</article-title><source>J Gerontol</source><year>1994</year><volume>49</volume><fpage>M85</fpage><lpage>M94</lpage><pub-id pub-id-type="doi">10.1093/geronj/49.2.M85</pub-id><pub-id pub-id-type="pmid">8126356</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freire</surname><given-names>AN</given-names></name><name><surname>Guerra</surname><given-names>RO</given-names></name><name><surname>Alvarado</surname><given-names>B</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Zunzunegui</surname><given-names>MV</given-names></name></person-group><article-title>Validity and reliability of the short physical performance battery in two diverse older adult populations in Quebec and Brazil</article-title><source>J Aging Health</source><year>2012</year><volume>24</volume><fpage>863</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1177/0898264312438551</pub-id><pub-id pub-id-type="pmid">22422762</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>G</given-names></name><name><surname>Peters</surname><given-names>L</given-names></name></person-group><article-title>The psychometric properties of the Composite International Diagnostic Interview</article-title><source>Soc Psychiatry Psychiatr Epidemiol</source><year>1998</year><volume>33</volume><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s001270050026</pub-id><pub-id pub-id-type="pmid">9503991</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Epstein</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>G</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name></person-group><article-title>An inventory for measuring clinical anxiety: psychometric properties</article-title><source>J Consult Clin Psychol</source><year>1988</year><volume>56</volume><fpage>893</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1037/0022-006X.56.6.893</pub-id><pub-id pub-id-type="pmid">3204199</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julian</surname><given-names>LJ</given-names></name></person-group><article-title>Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A)</article-title><source>Arthritis Care Res (Hoboken )</source><year>2011</year><volume>63</volume><issue>Suppl 11</issue><fpage>S467</fpage><lpage>S472</lpage><pub-id pub-id-type="doi">10.1002/acr.20561</pub-id><pub-id pub-id-type="pmid">22588767</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Ponds</surname><given-names>RW</given-names></name><name><surname>Houx</surname><given-names>PJ</given-names></name><name><surname>Jolles</surname><given-names>J</given-names></name></person-group><article-title>Effect of test duration on age-related differences in Stroop interference</article-title><source>J Clin Exp Neuropsychol</source><year>1997</year><volume>19</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1080/01688639708403838</pub-id><pub-id pub-id-type="pmid">9071643</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Brooks</surname><given-names>R</given-names></name><name><surname>Rabin</surname><given-names>R</given-names></name><name><surname>de Charro</surname><given-names>F</given-names></name></person-group><source>The measurement and valuation of health status using EQ-5D: a European perspective</source><year>2003</year><publisher-loc>Dordrecht</publisher-loc><publisher-name>Kluwer Academic publishers</publisher-name></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kind</surname><given-names>P</given-names></name><name><surname>Dolan</surname><given-names>P</given-names></name><name><surname>Gudex</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name></person-group><article-title>Variations in population health status: results from a United Kingdom national questionnaire survey</article-title><source>BMJ</source><year>1998</year><volume>316</volume><fpage>736</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1136/bmj.316.7133.736</pub-id><pub-id pub-id-type="pmid">9529408</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MR</given-names></name><name><surname>Hwang</surname><given-names>HF</given-names></name><name><surname>Hu</surname><given-names>MH</given-names></name><name><surname>Wu</surname><given-names>HDI</given-names></name><name><surname>Wang</surname><given-names>YW</given-names></name><name><surname>Huang</surname><given-names>FC</given-names></name></person-group><article-title>Psychometric comparisons of the timed up and go, one-leg stand, functional reach, and Tinetti balance measures in community-dwelling older people</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><fpage>1343</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2004.52366.x</pub-id><pub-id pub-id-type="pmid">15271124</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostenbrink</surname><given-names>JB</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Rutten</surname><given-names>FFH</given-names></name></person-group><article-title>Standardisation of costs: the Dutch Manual for Costing in economic evaluations</article-title><source>Pharmacoeconomics</source><year>2002</year><volume>20</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.2165/00019053-200220070-00002</pub-id><pub-id pub-id-type="pmid">12093300</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouwmans</surname><given-names>C</given-names></name><name><surname>De Jong</surname><given-names>K</given-names></name><name><surname>Timman</surname><given-names>R</given-names></name><name><surname>Zijlstra-Vlasveld</surname><given-names>M</given-names></name><name><surname>Van der Feltz-Cornelis</surname><given-names>C</given-names></name><name><surname>Tan Swan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P)</article-title><source>BMC Health Serv Res</source><year>2013</year><volume>13</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.1186/1472-6963-13-217</pub-id><pub-id pub-id-type="pmid">23768141</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stel</surname><given-names>VS</given-names></name><name><surname>Smit</surname><given-names>JH</given-names></name><name><surname>Pluijm</surname><given-names>SMF</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Deeg</surname><given-names>DJH</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer</article-title><source>J Clin Epidemiol</source><year>2004</year><volume>57</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2003.07.008</pub-id><pub-id pub-id-type="pmid">15066685</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Schoor</surname><given-names>NM</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Worldwide vitamin D status</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2011</year><volume>25</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2011.06.007</pub-id><pub-id pub-id-type="pmid">21872807</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijboer</surname><given-names>AC</given-names></name><name><surname>Blankenstein</surname><given-names>MA</given-names></name><name><surname>Kema</surname><given-names>IP</given-names></name><name><surname>Buijs</surname><given-names>MM</given-names></name></person-group><article-title>Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration</article-title><source>Clin Chem</source><year>2012</year><volume>58</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2011.176545</pub-id><pub-id pub-id-type="pmid">22247500</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veer-Tazelaar</surname><given-names>PJ</given-names></name><name><surname>van Marwijk</surname><given-names>HWJ</given-names></name><name><surname>van Oppen</surname><given-names>P</given-names></name><name><surname>van Hout</surname><given-names>HPJ</given-names></name><name><surname>van der Horst</surname><given-names>HE</given-names></name><name><surname>Cuijpers</surname><given-names>P</given-names></name><etal/></person-group><article-title>Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial</article-title><source>Arch Gen Psychiatry</source><year>2009</year><volume>66</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2008.555</pub-id><pub-id pub-id-type="pmid">19255379</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perera</surname><given-names>S</given-names></name><name><surname>Mody</surname><given-names>SH</given-names></name><name><surname>Woodman</surname><given-names>RC</given-names></name><name><surname>Studenski</surname><given-names>SA</given-names></name></person-group><article-title>Meaningful change and responsiveness in common physical performance measures in older adults</article-title><source>J Am Geriatr Soc</source><year>2006</year><volume>54</volume><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2006.00701.x</pub-id><pub-id pub-id-type="pmid">16696738</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogendijk</surname><given-names>E</given-names></name><name><surname>van Groenou</surname><given-names>MB</given-names></name><name><surname>van Tilburg</surname><given-names>T</given-names></name><name><surname>Deeg</surname><given-names>D</given-names></name></person-group><article-title>Educational differences in functional limitations: comparisons of 55-65-year-olds in the Netherlands in 1992 and 2002</article-title><source>Int J Public Health</source><year>2008</year><volume>53</volume><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1007/s00038-008-8079-9</pub-id><pub-id pub-id-type="pmid">19112590</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>van Buuren</surname><given-names>S</given-names></name><name><surname>Oudshoorn</surname><given-names>C</given-names></name></person-group><source>Multivariate imputation by chained equations</source><year>2000</year><publisher-loc>Leiden</publisher-loc><publisher-name>TNO Prevention and Health, Public Health</publisher-name></element-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">World Health Organization: The global burden of disease 2004 update. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/">http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/</ext-link>. (2008). Accessed 20 July 2015.</mixed-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spedding</surname><given-names>S</given-names></name></person-group><article-title>Vitamin D, and depression: a systematic review and meta-analysis comparing studies with and without biological flaws</article-title><source>Nutrients</source><year>2014</year><volume>6</volume><fpage>1501</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.3390/nu6041501</pub-id><pub-id pub-id-type="pmid">24732019</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lansdowne</surname><given-names>AT</given-names></name><name><surname>Provost</surname><given-names>SC</given-names></name></person-group><article-title>Vitamin D3 enhances mood in healthy subjects during winter</article-title><source>Psychopharmacology (Berl)</source><year>1998</year><volume>135</volume><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1007/s002130050517</pub-id><pub-id pub-id-type="pmid">9539254</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorde</surname><given-names>R</given-names></name><name><surname>Sneve</surname><given-names>M</given-names></name><name><surname>Figenschau</surname><given-names>Y</given-names></name><name><surname>Svartberg</surname><given-names>J</given-names></name><name><surname>Waterloo</surname><given-names>K</given-names></name></person-group><article-title>Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial</article-title><source>J Intern Med</source><year>2008</year><volume>264</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2008.02008.x</pub-id><pub-id pub-id-type="pmid">18793245</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>KM</given-names></name><name><surname>Stuart</surname><given-names>AL</given-names></name><name><surname>Williamson</surname><given-names>EJ</given-names></name><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Nicholson</surname><given-names>G</given-names></name><etal/></person-group><article-title>Annual high-dose vitamin D3 and mental well-being: randomised controlled trial</article-title><source>Br J Psychiatry</source><year>2011</year><volume>198</volume><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1192/bjp.bp.110.087544</pub-id><pub-id pub-id-type="pmid">21525520</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>AJ</given-names></name><name><surname>Bellgrove</surname><given-names>MA</given-names></name><name><surname>Hall</surname><given-names>T</given-names></name><name><surname>Phan</surname><given-names>WMJ</given-names></name><name><surname>Eyles</surname><given-names>DW</given-names></name><name><surname>Kvaskoff</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of vitamin D supplementation on cognitive and emotional functioning in young adults--a randomised controlled trial</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0025966</pub-id><pub-id pub-id-type="pmid">22073146</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertone-Johnson</surname><given-names>ER</given-names></name><name><surname>Powers</surname><given-names>SI</given-names></name><name><surname>Spangler</surname><given-names>L</given-names></name><name><surname>Larson</surname><given-names>J</given-names></name><name><surname>Michael</surname><given-names>YL</given-names></name><name><surname>Millen</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Vitamin D supplementation and depression in the women's health initiative calcium and vitamin D trial</article-title><source>Am J Epidemiol</source><year>2012</year><volume>176</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/aje/kwr482</pub-id><pub-id pub-id-type="pmid">22573431</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yalamanchili</surname><given-names>V</given-names></name><name><surname>Gallagher</surname><given-names>JC</given-names></name></person-group><article-title>Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms</article-title><source>Menopause</source><year>2012</year><volume>19</volume><fpage>697</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1097/gme.0b013e31823bcec5</pub-id><pub-id pub-id-type="pmid">22205149</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grady</surname><given-names>D</given-names></name><name><surname>Halloran</surname><given-names>B</given-names></name><name><surname>Cummings</surname><given-names>S</given-names></name><name><surname>Leveille</surname><given-names>S</given-names></name><name><surname>Wells</surname><given-names>L</given-names></name><name><surname>Black</surname><given-names>D</given-names></name><etal/></person-group><article-title>1,25-Dihydroxyvitamin D3 and muscle strength in the elderly: a randomized controlled trial</article-title><source>J Clin Endocrinol Metab</source><year>1991</year><volume>73</volume><fpage>1111</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1210/jcem-73-5-1111</pub-id><pub-id pub-id-type="pmid">1939527</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Begerow</surname><given-names>B</given-names></name><name><surname>Minne</surname><given-names>HW</given-names></name><name><surname>Abrams</surname><given-names>C</given-names></name><name><surname>Nachtigall</surname><given-names>D</given-names></name><name><surname>Hansen</surname><given-names>C</given-names></name></person-group><article-title>Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women</article-title><source>J Bone Miner Res</source><year>2000</year><volume>15</volume><fpage>1113</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2000.15.6.1113</pub-id><pub-id pub-id-type="pmid">10841179</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>HA</given-names></name><name><surname>Stahelin</surname><given-names>HB</given-names></name><name><surname>Dick</surname><given-names>W</given-names></name><name><surname>Akos</surname><given-names>R</given-names></name><name><surname>Knecht</surname><given-names>M</given-names></name><name><surname>Salis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial</article-title><source>J Bone Miner Res</source><year>2003</year><volume>18</volume><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2003.18.2.343</pub-id><pub-id pub-id-type="pmid">12568412</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>AM</given-names></name><name><surname>Biskup</surname><given-names>B</given-names></name><name><surname>Robbins</surname><given-names>B</given-names></name><name><surname>Marcella</surname><given-names>G</given-names></name><name><surname>Burleson</surname><given-names>JA</given-names></name></person-group><article-title>Effects of vitamin D supplementation on strength, physical function, and health perception in older, community-dwelling men</article-title><source>J Am Geriatr Soc</source><year>2003</year><volume>51</volume><fpage>1762</fpage><lpage>1767</lpage><pub-id pub-id-type="doi">10.1046/j.1532-5415.2003.51561.x</pub-id><pub-id pub-id-type="pmid">14687355</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latham</surname><given-names>NK</given-names></name><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Moseley</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>ID</given-names></name></person-group><article-title>A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects (FITNESS)</article-title><source>J Am Geriatr Soc</source><year>2003</year><volume>51</volume><fpage>291</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1046/j.1532-5415.2003.51101.x</pub-id><pub-id pub-id-type="pmid">12588571</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>JC</given-names></name></person-group><article-title>The effects of calcitriol on falls and fractures and physical performance tests</article-title><source>J Steroid Biochem Mol Biol</source><year>2004</year><volume>89&#x02013;90</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2004.03.059</pub-id><pub-id pub-id-type="pmid">15225827</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Iwamoto</surname><given-names>J</given-names></name><name><surname>Kanoko</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name></person-group><article-title>Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial</article-title><source>Cerebrovasc Dis</source><year>2005</year><volume>20</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1159/000087203</pub-id><pub-id pub-id-type="pmid">16088114</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name><name><surname>Conzelmann</surname><given-names>M</given-names></name><name><surname>Stahelin</surname><given-names>HB</given-names></name><name><surname>Dick</surname><given-names>W</given-names></name><name><surname>Carpenter</surname><given-names>MG</given-names></name><name><surname>Adkin</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?</article-title><source>Osteoporos Int</source><year>2006</year><volume>17</volume><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/s00198-005-0030-9</pub-id><pub-id pub-id-type="pmid">16508700</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunout</surname><given-names>D</given-names></name><name><surname>Barrera</surname><given-names>G</given-names></name><name><surname>Leiva</surname><given-names>L</given-names></name><name><surname>Gattas</surname><given-names>V</given-names></name><name><surname>de la Maza</surname><given-names>MP</given-names></name><name><surname>Avendano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects</article-title><source>Exp Gerontol</source><year>2006</year><volume>41</volume><fpage>746</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2006.05.001</pub-id><pub-id pub-id-type="pmid">16797903</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smedshaug</surname><given-names>GB</given-names></name><name><surname>Pedersen</surname><given-names>JI</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name></person-group><article-title>Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blind controlled trial</article-title><source>Scand J Food Nutrition</source><year>2007</year><volume>51</volume><fpage>74</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1080/03461230701422528</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>RL</given-names></name><name><surname>Cochrane</surname><given-names>B</given-names></name><name><surname>Jackson</surname><given-names>RD</given-names></name><name><surname>Larson</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>C</given-names></name><name><surname>Limacher</surname><given-names>M</given-names></name><etal/></person-group><article-title>Calcium, vitamin D supplementation, and physical function in the Women's Health Initiative</article-title><source>J Am Diet Assoc</source><year>2008</year><volume>108</volume><fpage>1472</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1016/j.jada.2008.06.432</pub-id><pub-id pub-id-type="pmid">18755319</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira-Pfrimer</surname><given-names>LDF</given-names></name><name><surname>Pedrosa</surname><given-names>MAC</given-names></name><name><surname>Teixeira</surname><given-names>L</given-names></name><name><surname>Lazaretti-Castro</surname><given-names>M</given-names></name></person-group><article-title>Treatment of vitamin D deficiency increases lower limb muscle strength in institutionalized older people independently of regular physical activity: a randomized double-blind controlled trial</article-title><source>Ann Nutr Metab</source><year>2009</year><volume>54</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1159/000235874</pub-id><pub-id pub-id-type="pmid">19729890</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Begerow</surname><given-names>B</given-names></name><name><surname>Minne</surname><given-names>HW</given-names></name><name><surname>Suppan</surname><given-names>K</given-names></name><name><surname>Fahrleitner-Pammer</surname><given-names>A</given-names></name><name><surname>Dobnig</surname><given-names>H</given-names></name></person-group><article-title>Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals</article-title><source>Osteoporos Int</source><year>2009</year><volume>20</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1007/s00198-008-0662-7</pub-id><pub-id pub-id-type="pmid">18629569</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Songpatanasilp</surname><given-names>T</given-names></name><name><surname>Chailurkit</surname><given-names>LO</given-names></name><name><surname>Nichachotsalid</surname><given-names>A</given-names></name><name><surname>Chantarasorn</surname><given-names>M</given-names></name></person-group><article-title>Combination of alfacalcidol with calcium can improve quadriceps muscle strength in elderly ambulatory Thai women who have hypovitaminosis D: a randomized controlled trial</article-title><source>J Med Assoc Thai</source><year>2009</year><volume>92</volume><issue>5</issue><fpage>S30</fpage><lpage>S41</lpage><pub-id pub-id-type="pmid">19894330</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>HCJP</given-names></name><name><surname>Samson</surname><given-names>MM</given-names></name><name><surname>Verhaar</surname><given-names>HJJ</given-names></name></person-group><article-title>Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation</article-title><source>Aging Clin Exp Res</source><year>2010</year><volume>22</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1007/BF03324819</pub-id><pub-id pub-id-type="pmid">20305368</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>Binkley</surname><given-names>N</given-names></name><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Recker</surname><given-names>R</given-names></name><name><surname>Samanta</surname><given-names>S</given-names></name><name><surname>Cohn</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Once-weekly dose of 8400&#x000a0;IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency</article-title><source>Am J Clin Nutr</source><year>2010</year><volume>91</volume><fpage>985</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2009.28113</pub-id><pub-id pub-id-type="pmid">20130093</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witham</surname><given-names>MD</given-names></name><name><surname>Crighton</surname><given-names>LJ</given-names></name><name><surname>Gillespie</surname><given-names>ND</given-names></name><name><surname>Struthers</surname><given-names>AD</given-names></name><name><surname>McMurdo</surname><given-names>MET</given-names></name></person-group><article-title>The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial</article-title><source>Circ Heart Fail</source><year>2010</year><volume>3</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.109.907899</pub-id><pub-id pub-id-type="pmid">20103775</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Austin</surname><given-names>N</given-names></name><name><surname>Devine</surname><given-names>A</given-names></name><name><surname>Bruce</surname><given-names>D</given-names></name><name><surname>Prince</surname><given-names>RL</given-names></name></person-group><article-title>A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency</article-title><source>J Am Geriatr Soc</source><year>2010</year><volume>58</volume><fpage>2063</fpage><lpage>2068</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2010.03142.x</pub-id><pub-id pub-id-type="pmid">21054285</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glendenning</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Inderjeeth</surname><given-names>C</given-names></name><name><surname>Howat</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>JR</given-names></name><name><surname>Prince</surname><given-names>RL</given-names></name></person-group><article-title>Effects of three-monthly oral 150,000&#x000a0;IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial</article-title><source>J Bone Miner Res</source><year>2012</year><volume>27</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1002/jbmr.524</pub-id><pub-id pub-id-type="pmid">21956713</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornikx</surname><given-names>M</given-names></name><name><surname>Van Remoortel</surname><given-names>H</given-names></name><name><surname>Lehouck</surname><given-names>A</given-names></name><name><surname>Mathieu</surname><given-names>C</given-names></name><name><surname>Maes</surname><given-names>K</given-names></name><name><surname>Gayan-Ramirez</surname><given-names>G</given-names></name><etal/></person-group><article-title>Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial</article-title><source>Respir Res</source><year>2012</year><volume>13</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-13-84</pub-id><pub-id pub-id-type="pmid">23006613</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampman</surname><given-names>MT</given-names></name><name><surname>Steffensen</surname><given-names>LH</given-names></name><name><surname>Mellgren</surname><given-names>SI</given-names></name><name><surname>Jorgensen</surname><given-names>L</given-names></name></person-group><article-title>Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial</article-title><source>Mult Scler</source><year>2012</year><volume>18</volume><fpage>1144</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1177/1352458511434607</pub-id><pub-id pub-id-type="pmid">22354743</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Kishimoto</surname><given-names>KN</given-names></name><name><surname>Okuno</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Oizumi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of alfacalcidol on back extensor strength gained through back extensor exercise in postmenopausal women with osteoporosis</article-title><source>Am J Phys Med Rehabil</source><year>2013</year><volume>92</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1097/PHM.0b013e31826ed991</pub-id><pub-id pub-id-type="pmid">23044701</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAlindon</surname><given-names>T</given-names></name><name><surname>LaValley</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Nuite</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Price</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial</article-title><source>JAMA</source><year>2013</year><volume>309</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.164487</pub-id><pub-id pub-id-type="pmid">23299607</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanghi</surname><given-names>D</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>AC</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Natu</surname><given-names>SM</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial</article-title><source>Clin Orthop Relat Res</source><year>2013</year><volume>471</volume><fpage>3556</fpage><lpage>3562</lpage><pub-id pub-id-type="doi">10.1007/s11999-013-3201-6</pub-id><pub-id pub-id-type="pmid">23904246</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knutsen</surname><given-names>KV</given-names></name><name><surname>Madar</surname><given-names>AA</given-names></name><name><surname>Lagerlov</surname><given-names>P</given-names></name><name><surname>Brekke</surname><given-names>M</given-names></name><name><surname>Raastad</surname><given-names>T</given-names></name><name><surname>Stene</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway</article-title><source>J Clin Endocrinol Metab</source><year>2014</year><volume>99</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2647</pub-id><pub-id pub-id-type="pmid">24248184</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>AD</given-names></name><name><surname>Secombes</surname><given-names>KR</given-names></name><name><surname>Thies</surname><given-names>F</given-names></name><name><surname>Aucott</surname><given-names>LS</given-names></name><name><surname>Black</surname><given-names>AJ</given-names></name><name><surname>Reid</surname><given-names>DM</given-names></name><etal/></person-group><article-title>A parallel group double-blind RCT of vitamin D3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity?</article-title><source>Osteoporos Int</source><year>2014</year><volume>25</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/s00198-013-2473-8</pub-id><pub-id pub-id-type="pmid">23982800</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolighed</surname><given-names>L</given-names></name><name><surname>Rejnmark</surname><given-names>L</given-names></name><name><surname>Sikjaer</surname><given-names>T</given-names></name><name><surname>Heickendorff</surname><given-names>L</given-names></name><name><surname>Vestergaard</surname><given-names>P</given-names></name><name><surname>Mosekilde</surname><given-names>L</given-names></name><etal/></person-group><article-title>No beneficial effects of vitamin D supplementation on muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial</article-title><source>Eur J Endocrinol</source><year>2015</year><volume>172</volume><fpage>609</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1530/EJE-14-0940</pub-id><pub-id pub-id-type="pmid">25646406</pub-id></element-citation></ref></ref-list></back></article>